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Abstract: A comprehensive review of pharmacological and medical aspects of the
muscarinic class of acetylcholine agonists and antagonists is presented. The therapeutic
benefits of achieving receptor subtype selectivity are outlined and applications in the
treatment of Alzheimer’s disease are discussed. A selection of chemical routes are
described, which illustrate contemporary methodology for the synthesis of chiral
medicinal compounds (asymmetric synthesis, chiral pool, enzymes). Routes to bicyclic
intrannular amines and intramolecular Diels-Alder reactions are highlighted.
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1 The Pharmacology of Muscarinic Receptors
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Muscarinic receptors are the receptor sites for the neurotransmitter of the parasympathetic
autonomic nervous system, acetylcholine (Ach, 1a). Their primary location is on the post-synaptic cell
membranes of smooth muscle, cardiac muscle and glandular tissue at the ends of parasympathetic
nerve pathways. Muscarinic receptors are therefore responsible for mediating the physiological effects
of parasympathetic nerve activity (Fig 1). These responses include; cardiac slowing, contraction of a
wide range of smooth muscles (gastro-intestinal tract, detrusor muscle of the bladder, bronchioles,
urethra, gall bladder and ducts, iris circular muscle, seminal vesicles and vas deferens), vasodilatation
and increased secretion from exocrine glands (salivary glands, mucosal glands of the airways, gastric
acid secretion and lachrymal secretion). The secretion of sweat is anatomically and physiologically a
sympathetic response, but is mediated via the release of Ach onto muscarinic receptors. Acetylcholine
interacts with two receptor types; termed muscarinic and nicotinic because the responses can be
selectively mimicked by the alkaloids muscarine (2) and nicotine (3). The effects of stimulating these
receptors can be distinguished by atropine (4) which is a competitive antagonist of muscarinic
receptors and not nicotinic receptors. The main locations of nicotinic receptors are autonomic ganglia,
the adrenal medulla, causing release of adrenaline, and the neuromuscular junctions in skeletal muscle
[1].
As well as post-synaptically at parasympathetic nerve endings, muscarinic receptors have other
locations. They are present on the ends of peripheral parasympathetic neurones (i.e. pre-synaptically)
where they are responsible for auto-inhibition of transmitter release [2]. A further location is on the
autonomic ganglia where the main process of neurotransmission is through Ach interacting with
nicotinic receptors. However, muscarinic receptors are also present and are responsible for a secondary
inhibitory component of transmission and a final slow depolarisation of the ganglionic cell body [3].
Muscarinic receptors are also widely distributed in the brain where they have both pre- and post-
synaptic locations.
Drugs may interact with muscarinic receptors acting as agonists, stimulating and therefore
mimicking the effects of endogenous Ach, or they may be antagonists, preventing the normal
parasympathetic functions of the body and allowing sympathetic activity to predominate. Because of
the wide range of locations of muscarinic receptors and responses to their stimulation or blockade, a
variety of therapeutic applications have been known for many years.
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Figure 1 Muscarinic receptors at different locations along the autonomic parasympathetic
efferent pathway. Acetylcholine (Ach) released from the preganglionic varicosity can
interact with nicotinic NN, muscarinic M1 and muscarinic M2 receptors to produce a fast
depolarisation (fast EPSP), a slow depolarization (slow EPSP) and hyperpolarization
(IPSP), respectively. Nicotinic receptor stimulation sets up the action potential in the
postganglionic neurone to release Ach from parasympathetic nerve terminal varicosities.
This can interact with M2 or M3 receptors in smooth muscle.
A vast number of naturally occurring and synthetic agents have been available for some time but in
general these show no tissue selectivity and therefore if aimed at a specific target will tend to produce
undesirable side effects at other sites. More recently, the search has been for selective compounds and
this has been primarily based on the fact that muscarinic receptors are now known to exist as at least
five subtypes. The distribution of these receptor subtypes differs and tissue responses are mediated by
the different subtypes. This review will deal with the muscarinic receptors involved in the various
tissue responses, the current and potential therapeutic applications of stimulating or blocking these
receptors, the medicinal chemistry of agents that interact with muscarinic receptors and the attempts to
achieve selectivity among agonists and antagonists. Compounds with these muscarinic properties have
a diverse range of structures and generalisations are readily confounded. Nevertheless the majority of
the compounds have a basic nitrogen and a surrogate for the acetate group of acetylcholine (1a) and/or
an aromatic moiety. Accordingly throughout this review, the chemical structures are drawn with the
most basic nitrogen on the left and the acetate surrogate on the right whenever practically possible, to
match the structures for acetylcholine (1a) and muscarine (2). Some amines are shown as the free base
and others as the salt. The structure depicted is consistent with that assigned to the name of the
compound, which may be for the salt or the free base. Anionic counterions are not shown unless they
are relevant.
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1.2 Muscarinic Receptor Subtypes
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The possibility of more than one muscarinic receptor was first suggested by the preferential binding
of the antagonist pirenzepine (5) to certain areas of brain tissue and autonomic ganglia rather than to
smooth and cardiac muscle [4]. By the use of functional tissue responses and radioligand binding to
tissue homogenates it is now clear that there are three firmly identified muscarinic receptors, M1, M2
and M3, with a fourth M4 now gaining acceptance (Table 1) [5]. Molecular biological techniques have
resulted in the cloning of five muscarinic receptor cDNAs, designated m1 to m5, which encode the
corresponding muscarinic receptor. When expressed in mammalian cell lines, these cloned receptors
(identified by the lower case m) have the pharmacological characteristics of the M1 to M4 natural
receptors. An M5 receptor has yet to be identified for a functional response, although recently m5
receptor binding sites have been proposed in certain brain regions after all other muscarinic receptor
types have been occluded [6]. The amino acid sequences of the m1 to m5 receptors have been identified
for several species including humans. There are a number of similarities in the amino acid residues of
the m1 and m3 receptor compared with the m2 and m4 sequences. Muscarinic receptors belong to the
super-family of G protein-linked receptors in which the amino acid chain spans the cell membrane
seven times, with each hydrophobic trans-membrane domain formed into an α-helix. These α-helixes
are arranged around a central pocket that serves as the point of entry of the agonist or antagonist and
specific amino acid residues provide the groups for the drug receptor interactions.
The coupling of muscarinic receptors to the pharmacological response is through the G protein
primarily at the third intracellular loop. Agonist activation of the receptor causes replacement of GDP
with GTP binding to the α-subunit of the G protein which is then cleaved from the β- and γ-subunits.
The GTP-bound α-subunit is thereby activated and stimulates or inhibits the activity of intracellular
enzymes involved in the production of second messengers linked to the tissue response. M1, M3 and m5
receptors are linked through G protein of the Gq family to stimulation of phosphoinosidase C
(PIC)[also known as phospholipase C, PLC]. PIC hydrolyses phosphoinositides including
phosphatidylinositol 4,5-bisphosphate (PIP2), which forms inositol 1,4,5-triphosphate (IP3) and 1,2-
diacylglycerol (DAG).  IP3 and possibly DAG are second messengers for responses mediated via M1,
M3 and m5 receptors. IP3 binds to receptor sites on the intracellular sarcoplasmic reticulum stores for
Ca2+ and causes release of Ca2+ to initiate smooth muscle contraction and glandular secretion (M3
responses). DAG stimulates protein kinase C which initiates phosphorylation of key proteins involved
in muscle contraction and Ca2+ influx.
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Table 1. Muscarinic receptors, second messengers and tissue responses
Receptor
subtype
Second
messenger
Organ/tissue Response
M1 IP3/DAG↑ autonomic ganglion depolarization, slow EPSP
including myenteric plexus increased gastric acid secretion via
vagus nerve
vas deferens (rabbit) reduced twitch height and NA release
brain (cerebral cortex) binding sites
canine saphenous vein contraction
M2 cAMP↓ and
direct
coupling to
K+ channel
heart -
atrium
sinu-atrial node
reduced contractile force (negative
inotropy)
reduced rate (negative chronotropy)
prejunctional at autonomic
nerve endings
reduced NA or Ach release
ileum smooth muscle predominant binding sites - uncertain
function
M3 IP3/DAG↑ smooth muscle -
gut
urinary bladder
trachea
iris circular muscle
contraction
minor binding sites
blood vessels-
endothelium
smooth muscle
release of NO and vasodilatation
contraction
glands -
oxyntic cells (gastric acid)
salivary glands
pancreatic β cells
increased acid secretion
salivation
insulin release
M4 cAMP↓ guinea-pig uterus contraction
rabbit anococcygeus muscle NO-dependent relaxation
rabbit lung binding sites
M5 IP3/DAG↑ brain regions binding sites after all others occluded
__________________________________________________________________________________
Abbreviations: Ach, acetylcholine; cAMP, cyclic adenosine 3',5'-monophosphate; DAG,
1,2-diacylglycerol; EPSP, slow depolarization; IP3, inositol 1,4,5-triphosphate; NA,
noradrenaline; NO, nitric oxide.
__________________________________________________________________________________
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In contrast, M2 and M4 receptors are coupled through Gi to the enzyme adenylyl cyclase. Cleavage
of the GTP-bound α-subunit of the G protein results in inhibition of adenylyl cyclase and a fall in the
levels of cyclic adenosine 3’,5’-monophosphate (cAMP) production from ATP. cAMP is a second
messenger for a number of receptor types including β-adrenoceptors and histamine H2 receptors, its
formation resulting in the activation of cAMP-dependent protein kinase (PKA) which produces tissue
responses by phosphorylating a number of substrates. Thus, M2 and M4 receptor-mediated responses
are brought about by inhibition of cAMP levels and inhibition of cAMP-dependent intracellular events.
M2 receptors may also be linked through G proteins directly to ion channels without an intermediate
second messenger, for example, in the heart [5, 7, 8, 9]. The muscarinic receptor subtypes, their second
messengers and the pharmacological responses are summarised in Table 1.
2 Pharmacological Effects of Agonists and Therapeutic Applications
2.1 Cardiovascular System
The heart is slowed by parasympathetic activity of the vagus nerve on the sinu-atrial node
pacemaker tissue, while ventricular contractility is only reduced when it is raised by sympathetic tone
(i.e. an antiadrenergic effect). These effects are due to M2 receptor stimulation. The direct effect on
nodal tissue is mainly due to direct coupling to K+ channels which are opened to allow K+ efflux,
hyperpolarization and a reduction of the action potential duration. This results in cardiac slowing
(bradycardia). The antiadrenergic activity is due to M2 receptor-mediated inhibition of cAMP
production [10].
Blood vessels do not normally receive a parasympathetic innervation, but they respond to
muscarinic agonists with a generalised vasodilatation and a fall in blood pressure. The vasodilator
action is due to the presence of M3 muscarinic receptors on the endothelial lining of the vessel.
Stimulation of these causes the release of nitric oxide (NO) by the action of nitric oxide synthase
(NOS) on L-arginine, the nitric oxide causing relaxation of the underlying smooth muscle through
accumulation of cGMP [11]. When the endothelium is removed or damaged, Ach (1a) can cause a
contraction or local spasm of the smooth muscle. The receptor type mediating this response is poorly
characterised and appears to be either of the M1 or M3 type depending on the vascular bed [12]. These
cardiovascular effects of muscarinic agonists are no longer made use of therapeutically. The use of the
vasodilator action of methacholine (6a) to treat vascular insufficiency, such as Raynaud’s syndrome,
has ceased because of its unreliability. However, the possibility of M2 receptor-mediated bradycardia
and circulatory collapse as a side effect of muscarinic agonists should not be overlooked.
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2.2 Gastrointestinal Tract
The response of the gut to muscarinic agonists is an increase in motility and smooth muscle
contraction (M3), increased secretions of gastric acid from the parietal (oxyntic) cells of the stomach
and of digestive enzymes throughout the gut. The effect of vagal stimulation is blocked by the M1
receptor-selective antagonist, pirenzepine (5), and attributed to antagonism of M1 receptors in the
parasympathetic ganglia of the gastric intramural plexus. The effects of agonists, however, are weakly
antagonised by pirenzepine and due to a direct action at M3 receptors on the oxyntic cell [13]. The
increase in intestinal motility by the non-selective agonist, bethanechol (6b), is utilised in cases of
postoperative gastric distension and atony and in non-obstructive adynamic (paralytic) ileus [14].
2.3 Other Smooth Muscle
Smooth muscle in the airways and other organs such as the urinary bladder (detrusor muscle), gall
bladder, vas deferens and urethra contracts in response to parasympathetic activation and muscarinic
agonists; the effects being mediated via M3 receptors. The only current use of these actions is in the
relief of postoperative and postpartum non-obstructive urinary retention. Although M3 receptors
exclusively mediate the contractions of smooth muscle from these organs and the gastrointestinal tract,
radioligand binding data has shown the presence of a mixed population of M2 and M3 receptors in most
of these tissues. Indeed, the M2 receptors outnumber the M3 receptors by about 4:1. This has been
confirmed by Northern blotting to determine the mRNA for the receptors and by immuno-precipitation
experiments to estimate the receptor protein species expressed. What then is the role of these more
abundant M2 receptors? It is proposed that they may provide an indirect component to the contractile
responses under certain conditions since they are negatively linked to adenylyl cyclase and stimulation
causes a decrease in cAMP levels. The reduction in cAMP would oppose the raised levels that
accompany the relaxation of smooth muscle induced by sympathetic nerve activity or
sympathomimetic amines. Thus, a contraction could ensue as result of this antagonism of relaxant tone.
It has been suggested therefore that selective M3 antagonists are not necessarily the ideal for treatment
of smooth muscle disorders, since they could expose an M2 receptor-mediated contraction [9].
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2.4 Glandular Secretions
Secretions from exocrine glands are uniformly stimulated by muscarinic agonists through M3
receptors. While these effects are probably mediated via the same receptor type as smooth muscle
contraction, there is some evidence for differences in the activities of antagonists. For example,
zamifenacin (7) and darifenacin (8) are M3 selective antagonists which show selectivity towards the
smooth muscle M3 receptors of the ileum compared with M3 receptors controlling salivary secretion
[15]. Furthermore, the M3 selective antagonist NPC-14,695 (9) showed selectivity for bronchial
smooth muscle compared with salivary secretion [16]. The reasons for this tissue selectivity are unclear
since the involvement of identical receptors should result in the same degree of antagonism. One
possibility is that receptor configuration or antagonist binding are affected by tissue-dependent factors
such as the signal transduction pathways (receptor coupling) or the presence of other receptor subtypes
which exert a modulating function [15].
2.5 The Eye
Parasympathetic nerves control of the circular (sphincter pupillae) muscle of the iris and the ciliary
muscle which alters the curvature of the lens. The iris circular muscle contracts via M3 receptors in
response to bright light, constricting the pupil. Contraction of the ciliary muscle accommodates the lens
for near vision and is also M3 receptor-mediated. The contraction of the iris away from the drainage
canal for the aqueous humour (canal of Schlemm) opens the drainage angle which facilitates its
drainage. This property of muscarinic agonists reduces the raised intraocular pressure that occurs in
glaucoma. Topical pilocarpine (10) has been widely used for many years in the treatment of wide-angle
and narrow-angle glaucoma [17]. Visual discomfort through M3 receptor stimulation remains a
problem with systemically administered muscarinic agonists.
2.6 Central Nervous System
Muscarinic receptors in the brain offer a major therapeutic target for muscarinic agonists in the
treatment of Alzheimer’s disease [18, 19, 20]. This is based on two aspects of the pathophysiology of
Alzheimer’s disease (AD) and memory dysfunction; the cholinergic hypothesis of memory dysfunction
and the muscarinic receptor regulation of amyloid metabolism. The loss of memory in AD is associated
with a cholinergic deficit, which takes the form of a selective decrease of cholinergic neurones in the
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ventral forebrain whose axons project into the cortex and hippocampus. These cholinergic projections
form vital components of the ascending reticular activating system which is involved in memory
function and attention. There is an associated reduction in the activity of choline acetyltransferase
(CAT), the enzyme responsible for synthesis of Ach. The postsynaptic muscarinic receptors upon
which these neurones impinge and therefore involved in cognitive function are of the M1 subtype.
Although the neurones are damaged in AD, the M1 receptors are not significantly reduced. Further
support for a role of central muscarinic receptors in memory is the observation that antagonists, such as
hyoscine (scopolamine, 11), impair memory [21].
(11) Hyoscine (scopolamine) 
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The second major histopathological change observed in AD is the presence of amyloid plaques,
together with neurofibrillary tangles in dead and dying neurones in the brain. Amyloid deposits consist
of aggregates of peptides having 40-43 amino acid residues and known as β-amyloid peptide (Aβ). Aβ
is derived from the cleavage of a family of glycoproteins termed amyloid precursor protein (APP) and
is neurotoxic [22]. In cultured cell lines transfected with m1 and m3 receptors, it has been shown that
the muscarinic agonist carbachol (1b) can reduce the secretion of Aβ [23]. In cells transfected with m2
and m4 receptors, APP processing was not affected by muscarinic agonists. The site of action of the M1
receptor agonist appears to be an increase in the activity of a protease, α-secretase, through
phosphoinositide turnover and stimulation of protein kinase C. α-Secretase cleaves the APP in the Aβ
domain so that Aβ cannot be produced from APP; muscarinic agonists therefore reduce the levels of
Aβ produced [24]. Thus, it appears that Ach acting on M1 receptors may prevent the deposition of
neurotoxic amyloid in the brain and thus influence the pathogenic process itself. Muscarinic agonists
selective for M1 receptors therefore have potentially a two-fold action in the treatment of AD;
stimulation of the postsynaptic receptors involved in memory and inhibition of amyloid deposition
[25].
Currently, treatment of AD by this approach is limited to the use of anticholinesterases which non-
selectively enhance the reduced levels of Ach [26-27]. Physostigmine (12a) has been reported to
induce small transient improvements in cognitive function in Alzheimer’s patients. Tacrine (13) [28] is
a reversible non-competitive inhibitor of cholinesterase with three-fold selectivity for
butyrylcholinesterase which has also shown improvements in these patients [29]. The clinical use of
tacrine (13) has however been restricted by its hepatotoxicity [30]. Another disadvantage of
anticholinesterases is that their activity may be self-limiting. The raised Ach levels could activate
autoinhibitory pre-synaptic M2 receptors which would reduce the levels of Ach released. Indeed,
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blockade of these pre-synaptic receptors offers an alternative approach to the treatment of AD, their
blockade would presumably enhance the release of Ach from the central neurones. Thus, an optimal
combination would be M1 agonism together with M2 antagonism [31]. L-687,306 (14) [32] and the
related chloropyrazine, L-689,660 (15) [33-34], display this type of property. The former has M1 partial
agonist activity and M2/M3 antagonistic activity, while L-689,660 is an M1 agonist, M3 partial agonist
and M2 antagonist based on functional tissue responses [35]. By radioligand binding analysis, however,
they show no selectivity of binding affinity [36](cf. ester surrogates). Talsaclidine (16) is also an M1
selective full agonist but M2 and M3 partial agonist [37] which is effective and well tolerated in Phase I
safety trials [38]. Thus, selectivity for M1 receptors through differential binding has been difficult to
achieve. The selectivity of the compounds described above has been attained by utilising differences in
receptor reserve for the various muscarinic receptor subtypes and their functional responses.
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3. Pharmacological Effects of Antagonists and Therapeutic Applications
3.1 Introduction
The prototype muscarinic antagonist is atropine, which is the racemate, (±)-hyoscyamine (4), of the
naturally occurring alkaloid from the Deadly Nightshade (Atropa belladonna). (-)-Hyoscyamine occurs
naturally, but racemisation takes place on heating and extraction. In spite of the synthesis of a wide
range of new antagonists, atropine remains one of the most potent antagonists available. (-)-
Hyoscyamine (or atropine) is a competitive antagonist without selectivity for any of the subtypes of
muscarinic receptor. It antagonises the effects of muscarinic agonists and of the parasympathetic
nervous system allowing sympathetic tone to dominate. In vivo, however, atropine (4) has differential
effects on the various organs of the body with the salivary and bronchial secretions being depressed by
low doses. As the dose is increased, so progressively more organs are affected, the order being pupil,
heart, bladder and gastrointestinal tract. Finally, large doses are required to inhibit gastric acid
secretion and motility. The reason for this is firstly the presence of pre-synaptic autoinhibitory M2
receptors, blockade of which by atropine allows the release of more Ach from parasympathetic
neurones to overcome the post-synaptic blockade. The second reason is that parasympathetic nerve
pathways in many organs contain non-adrenergic non-cholinergic components which release not Ach
but alternative or co-transmitters, including ATP. These contribute to the tissue response but are not
blocked by muscarinic antagonists. The degree of resistance to blockade varies between organs
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depending on the involvement of NANC pathways; in the bladder and gastrointestinal tract they are
particularly evident [1]. The therapeutic usefulness of non-selective antagonists like atropine is
restricted by their wide-spread effects. This may be an advantage, however, for example in the use of
hyoscine (11) and glycopyrrolate (17) in premedication for surgical procedures. The blockade of
salivary and mucus secretions, cardioprotection, block of smooth muscle spasm and a degree of
amnesia and sedation are desirable properties, although with modern anaesthetics the use of
antimuscarinic premedicants is less common these days.
3.2 Cardiovascular System
The heart rate is under parasympathetic tone via M2 receptors on the SA node, which are blocked
by atropine to cause tachycardia. There may be a paradoxical transient slowing of heart rate after slow
intravenous administration, probably because of initial blockade of the pre-synaptic M2 autoreceptors.
The tachycardia, however, predominates together with an increase in conduction velocity which
facilitates transmission of excitation to the ventricles via the AV node. This property of atropine (4) is
used in the emergency treatment of acute myocardial infarction when the dominant autonomic
influence on the heart is via the vagus nerve, causing sinus or nodal bradycardia. Selective M2 receptor
antagonists are therefore of potential value for this indication and AF-DX 116 (otenzepad) (18) is in
the latter stages of development for bradycardia [39].
3.3 Gastrointestinal Tract
Muscarinic antagonists inhibit the contractions of the gastrointestinal tract induced by Ach and
other muscarinic agonists mediated via M3 receptors. They are, however, generally less effective
against the increases in contractility and motility due to parasympathetic nerve stimulation. The reason
for this is the contribution of atropine-resistant NANC pathways to the contraction. The partial
inhibition of gastrointestinal motility by atropinic drugs has led to their widespread use as
antispasmodics in the treatment of disorders associated with intestinal hypermotility. The belladonna
alkaloids have long been used for the treatment of gastrointestinal upset, Tincture of Belladonna having
formerly been a common component of several widely used mixtures. Established non-selective
antimuscarinics, including dicyclomine (19), are used for the relief of intestinal colic due to muscle
spasm, particularly in children. An expanding market is also for the symptomatic treatment of
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diarrhoea associated with irritation of the lower bowel, such as mild dysenteries and diverticulitis,
known as irritable bowel syndrome (IBS). Existing drugs for the treatment of IBS, such as mebeverine
(20), cimetropium (21) and milverine (22), have additional properties including Ca2+ channel blockade
which contributes to their antispasmodic activity [40]. There is therefore a need for selective M3
receptor antagonists for the treatment of gastrointestinal tract disorders. Zamifenacin (7) and
darifenacin (8) show selectivity for M3 over M2 and M1 receptors and the latter has been in Phase II
clinical evaluation with encouraging results [15]. Since M3 receptors are also involved in the secretory
and miotic (pupil constriction) responses of muscarinic agonists, side effects of dry mouth and visual
discomfort are still likely with such antagonists. Darifenacin (8), however, shows selectivity towards
the ileum compared with salivary glands and other smooth muscle. The reasons for this are unclear at
present, but it has been suggested that this might indicate a difference in the M3 receptors in different
tissues. It would be advantageous to exploit these differences in developing newer more selective
compounds for use in gastrointestinal disorders [40].
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A different application for muscarinic antagonists in the gastrointestinal tract has been in the
treatment of peptic ulcers. Gastric acid secretion induced by parasympathetic nerve activity is due to a
direct action of Ach on the acid secreting parietal cells and an indirect effect through the release of
gastrin from the antrum of the stomach. The secretory responses of muscarinic agonists are blocked
predictably for an M3 receptor-mediated effect, so that the selective M1 receptor antagonist,
pirenzepine (5), is weakly effective. However, pirenzepine is more potent as an antagonist of secretion
induced by nerve stimulation. The site of action is probably inhibition of M1 receptors located on the
post-ganglionic nerves of the myenteric plexus. As a result of the inhibition of gastric acid secretion
and reduced gastric motility, antimuscarinic agents aid the healing of peptic ulcers. Widespread side-
effects arising from their non-selective blockade of muscarinic receptors and improved efficacy of
histamine H2 antagonists, cimetidine and ranitidine, have resulted in a decline in their use. The M1
selective antagonist pirenzepine (5), however, has a lower incidence of muscarinic side effects and is as
effective as cimetidine at promoting ulcer healing in patients with duodenal ulcer.
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3.4 Urinary Bladder
The contraction of the detrusor muscle of the body of the bladder in response to filling to a critical
level resulting in micturition is mediated via the action of Ach released from parasympathetic nerves
on M3 receptors. This response is inhibited by muscarinic antagonists and the ensuing urinary retention
is of value in the management of urinary incontinence (UI) [41]. They have widespread application in
urge incontinence in the elderly, in children suffering from nocturnal enuresis, and to reduce urinary
frequency in spastic paralysis. Urge incontinence occurs when there is an involuntary passing of urine
associated with a strong desire to void the bladder. Motor urge incontinence occurs where there is
increased contractile activity of the bladder brought on by outflow obstruction, inflammation or
irritation, such as that due to infection associated with cystitis. Stress incontinence is due to weakness
of the skeletal muscle associated with the external sphincter of the bladder and is therefore not
susceptible to antimuscarinic drugs. The muscarinic antagonists in current use include propantheline
(23) and emepronium (24). Being quaternary ammonium compounds, they are not transported into the
brain and therefore only have peripheral side effects, including dry mouth, blurred vision and
tachycardia, due to their non-selective blockade of muscarinic receptors.
N
O
O
O
(24) Emepronium
N
(23) Propantheline
The drug of choice for UI is oxybutynin (25), which is a non-selective muscarinic antagonist with
additional direct smooth muscle relaxant properties through Ca2+ channel blockade and local
anaesthesia. Terodiline (26) is a muscarinic antagonist with additional Ca2+ channel blocking activity
that gained a valuable place in the management of UI [42]. It was, however, withdrawn after reports of
serious heart rhythm disturbances attributed to depression of the SA node, which is probably unrelated
to muscarinic receptor blockade and therefore not likely to occur with other drugs in this class.
Tolterodine (27) is a new non-selective muscarinic antagonist that has bladder selectivity over salivary
secretions and has been shown to be well tolerated and effective in patients with UI with minimal
propensity to cause dry mouth [43].
(26) Terodiline(25) Oxybutynin
N
H O
O
OH
N
H
N
HO
R R
(27a) R = H; (+)-Tolterodine 
(27b) R = OH; 5-Hydroxy-tolterodine
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As with gastrointestinal applications, there is an advantage from M3 receptor selective antagonists
and several of these are in development. The limitations are again that M3 receptors are also involved
in salivary secretion and eye functions, leading to potential for appropriate side effects. M3 selective
compounds displaying tissue selectivity for the bladder have been identified, including zarifenacin (7)
and vamicamide (28). The latter compound is more selective in vivo probably because of favourable
pharmacokinetics which allows it to be concentrated in the bladder, thereby exerting a localised
spasmolytic action [44].
(29) Ipratropium (30) Oxitropium 
N
O
OH
O
N
O
OH
S
O
O
 (28) Vamicamide
N
Ph
NH2
O
N
3.5 Airways
Parasympathetic innervation of the airways releases Ach onto M3 receptors which causes
bronchoconstriction and increased volume of mucous secretion (without altered viscosity). Blockade of
these effects by muscarinic antagonists is of limited use in the treatment of asthma but may be
beneficial during acute exacerbations of asthma. They are particularly useful in chronic obstructive
pulmonary disease (COPD) associated with emphysema and chronic bronchitis, which are regarded as
having non-reversible obstruction of the airways. Presumably the parasympathetic vagal tone to the
lungs is reversible [45]. A possible disadvantage of atropinic drugs is inhibition of ciliary beating and
therefore impaired mucociliary clearance.
Muscarinic antagonists currently in use, including ipratropium (29) and oxitropium (30), are non-
selective between receptor subtypes. Administered by inhalation they are virtually devoid of systemic
effects on the eye, bladder and heart, and the charged quaternary nitrogen atom prevents CNS effects.
An unexplained advantage of ipratropium (29) over atropine (4) is that it does not appear to impair
mucociliary clearance [46]. It would be an advantage to selectively block the M3 receptors mediating
bronchoconstriction and bronchial secretions, together with the M1 receptors involved in ganglionic
transmission of the vagal reflex pathways. Blockade of autoinhibitory presynaptic M2 receptors on the
parasympathetic nerve terminals would counteract these inhibitory actions by facilitating Ach release.
Thus agents selective for M3 and M1 receptors are currently being sought for use in the treatment of
COPD. Revatropate (31) is one such compound which has shown benefit in early clinical trials [15].
Tiotropium (32) has non-selective binding properties but achieves M3 selectivity because of a
preferential off-rate from M3 compared with M2 receptors [47].
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 (31) Revatropate, UK-112,166 (32) Tiotropium 
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O
O
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S
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N
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S
O
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3.6 The Eye
Muscarinic antagonists prevent the parasympathetic nerve-mediated contraction of the circular
muscle of the iris in response to bright light and the accompanying pupillary constriction. The
contraction of the ciliary body allowing the lens to accommodate for near vision is also blocked
(cycloplegia). Both of these effects are due to blockade of M3 receptors. The dilation of the pupil
(mydriasis) and relaxation of the iris into the drainage angle of the anterior chamber of the eye,
impedes drainage of aqueous humour into the canal of Schlemm. There is therefore a risk of raising
intraocular pressure and precipitating glaucoma of the narrow-angle type in susceptible individuals.
While muscarinic receptor antagonists have ophthalmic uses, mainly for dilating the pupil to make eye
examinations of the retina, the point of major importance is the risk of glaucoma and the
contraindication of their uses in patients at risk.
3.7 Prostate Gland
The human prostate gland is sparsely innervated by cholinergic nerves [48] and muscarinic
receptors of the M1 type have been found localised to the glandular epithelium, where they are
therefore primarily involved in secretory responses [49]. An involvement in cell proliferation is also
suggested and therefore a role in the hyperplasia of benign prostatic hypertrophy (BPH) [50]. This is a
common disorder affecting over 70% of men in their seventies which leads to difficulty in initiating
and completing the voiding of urine. Muscarinic agonists also cause contraction of isolated smooth
muscle strips from the prostatic stroma [51] and enhance contractions to field stimulation of guinea-pig
prostatic stroma, possibly through activation of presynaptic receptors facilitating noradrenergic
transmitter release. Muscarinic antagonists are generally regarded as being contraindicated in patients
with BPH because they interfere with the normal parasympathetic control of the bladder reflex.
However, in view of the involvement of muscarinic receptors in the prostate gland itself, there is an
argument for the use of M1 selective muscarinic antagonists in the treatment of BPH. We are not aware
of any clinical evidence for their effectiveness.
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4. The Medicinal Chemistry of Muscarinic Receptor Agonists and Antagonists
4.1 Scope
As noted in the introduction, muscarinic receptor agonists and particularly antagonists have a
diverse range of chemical structures. It is not feasible or perhaps even desirable within a review of this
length to make a broad survey of the field. Even a review of currently prescribed medicines or research
tools would be beyond the space allocated.  Therefore this section will concentrate on some recent
trends and highlight generic synthetic methods. Emphasis will also be given to anti-Alzheimer drugs in
view of the pressing need for effective treatments, albeit the efficacy of a muscarinic treatment
rationale for this area has yet to be established unequivocally. Towards the end of this section,
emphasis will also be given to natural products which have muscarinic activity, with the intention that
they may provide a spur to endeavours for the creation of new medicinal entities.
5. Muscarinic Agonists
It is a good general rule that muscarinic agonists are small molecules, whereas antagonists are large
molecules which frequently contain an aromatic moiety. This enforces an inherent conservatism in the
design of agonists. The designers of agonists must perforce be incrementalists, making modest but
significant structural modifications to obtain receptor sub-type selectivity, whereas the antagonist
designer works on a broader canvas and has the freedom to employ bold strokes of synthetic virtuosity.
5.1 Arecoline
Arecoline (33b) has been an important lead compound in this area. The free acid, arecaidine (33a)
(or acrecaine) and arecoline (33b) are obtained from betel or areca nuts (Areca catechu)[52-53]. These
have been chewed in many parts of Asia to induce salivation (a muscarinic property) and euphoria (a
nicotinic receptor stimulant property) [54]. Habitual chewing of these nuts is strongly correlated with
the incidence of oral cancer [55-56]. Arecoline has about 80% of the muscarinic activity of Ach (1a) at
physiological pH, and has been used to treat Alzheimer's' disease. Verbal memory was improved at low
doses [57-58], whereas attention and visuospatial abilities were improved at higher doses [59]. Low
doses were tolerated well [60], but high doses produced nausea and vomiting [61]. The optimum dose
varied fourfold from 4-16mg day [62] and about 20% of patients had no response whatsoever.
Unfortunately arecoline (33b) is orally ineffective, due to first-pass metabolism and all of these studies
were performed with intravenous perfusion of the drug. Attempts to develop a transdermal device were
confounded by skin inflammation [63], although this could be mitigated by modifying the vehicle [64]
and intranasal absorption is efficient [65]. The first step in the metabolism of arecoline by mice liver
homogenates is hydrolysis of the ester group by a carboxylesterase [66].
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N 
Me
OR
O
(33a) R = H; Arecaidine 
(33b) R = Me; Arecoline 
(33c) R = CH2C≡CH 
(33d) R = Et N 
Me
OMe
O
R
R
R
R
(34) One R = Me, 
all others = H
There have been two main strategies to improve the efficacy and selectivity of arecoline (33b).
Derivatives have been prepared in which the ester is replaced by a less or non-hydrolysable equivalent.
Alternatively the piperidine ring has been bridged to give rigid derivatives following the common
pharmacological dictum that rigidity confers selectivity. Consequently there are innumerable
muscarinic agonists based on the 1-aza-bicyclo[2.2.1]heptane (azanorbornane) and 1-aza-
bicyclo[2.2.2]octane (quinuclidine) skeletons bearing an ersatz ester group. The novelty in this area
derives from the choice of ester surrogate and, more rarely the means by which the ring system is
constructed. The exquisite sensitivity to substitution may be judged from the monomethyl-derivatives
(34) which were all antagonists-partial agonists. Even the ethyl derivative (33d) is only a partial
agonist [67] and N-desmethylarecoline (guvacoline) has a lower affinity for muscarinic receptors. The
propargyl ester (33c) is as potent as the methyl ester (33b), and is frequently used as a research tool
because it has slight M2 selectivity, however it is too easily hydrolysed to be a viable medicine [68].
5.2 Heterocyclic and Other Derivatives of Arecoline
Arecoline (33b) is commercially available and has served as the starting material for many
derivatives. Alternatively sodium borohydride reduction of pyridinium salts is an excellent way to
prepare 1,2,5,6-tetrahydropyridine derivatives, particularly if a substituent is present at the 3-position.
R H
N
OMe
(35a) N-desmethyl; RU 35963 
(35b) RU 35926
R H
N
O
(36a) N-desmethyl; RU  47029 
(36b) RU 35986
N 
Me
R =
The O-methyl (35) and O-propargyl (36) oxime derivatives of arecoline carboxaldehyde had potent
agonist properties in a battery of assays, with M1 selectivity over all other muscarinic receptor
subtypes. They also relieved scopolamine induced memory deficit in rats and mice at doses 2-3 orders
of magnitude lower than arecoline (33b) and had a longer duration of action [69-70]. 1,2,4-oxadiazoles
can be regarded as "cyclised" oxime derivatives. The methyl derivative (37) was more potent than
arecoline (33b), but had marginally lower efficacy [71]. The ethyl-triazole (38a) and the tetrazole (38b)
are both M1 agonists and M2 antagonists such that cholinergic side effects were only found at high
doses. Increasing the chain length at the 2-position decreases the efficacy and increases antagonistic
profiles [72].
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(33b) R -CO2Me;  
Arecoline
H2N
NHO
NaH, THF, MS, reflux, 
4h (82%)
N
R =
N
O
NR
(37)
NN
X
NR
Et
(38a) X = CH 
(38b) X = N
R
N
N
S
nHexylO
(39) Xanomeline, WAY-131256
N
NnHexylO
R
(40)
Xanomeline (39) has emerged as one of the most potent unbridged arecoline derivatives. It has
higher potency and efficacy for m1 and m4 than for m2, m3 and m5 receptor subtypes [73], binds to the
m1 receptor subtype uniquely tightly [74-75] and stimulates phosphoinositide hydrolysis in the brain. In
cells containing human m1 receptors which are stably expressing amyloid precursor protein (APP),
xanomeline (39) stimulates APP release with a potency 1000 greater than carbachol and reduces the
secretion of Aβ by 46% [76] (cf 2.6 Central nervous system). In patients with Alzheimer's disease, it
halted cognitive decline and reduced behavioural symptoms such as hallucinations, delusions and vocal
outbursts [77-78]. As might be expected there have been numerous attempts to prepare analogues with
comparable potency and efficacy. Transplanting the thiadiazole ring of xanomeline to a range of
bicyclic amines reduced selectivity [79-80] as did the use of pyrazine analogues (40) [81].
5.3 The Synthesis of 1-Aza-bicyclo[2.2.1]heptanes (1-Azanorbornanes) and 1-Aza-bicyclo-
[2.2.2]-octanes (Quinuclidines)
Methods for the synthesis of muscarinics based on the 1-aza-norbornane and quinuclidine skeletons
almost invariably commence with the ketones (41) or the hydroxymethyl-derivatives (42) or
derivatives at a higher oxidation state. Of these four compounds only quinuclidinone (41b) and
quinuclidinol (52) are commercially available and the latter costs circa £1.50/grm. Quinuclidinol (52)
is an intermediate in the synthesis of [3H]-quinuclidinyl benzilate (QNB) and the N-methyl derivative
which are frequently used as non-selective muscarinic antagonists in pharmacological experiments.
There are surprisingly few syntheses of quinuclidine derivatives and fewer of 1-aza-norbornanes and
many are low yielding. In short, the synthesis of these compounds is comparatively undeveloped and
the brief review of synthetic methods presented here is intended to spur further developments in this
area.
N
(CH2)n
O
N
(CH2)n
OH
(41a) n = 1 
(41b) n = 2
(42a) n = 1 
(42b) n = 2
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5.3.1 Intramolecular Nucleophilic Displacement by Amines
The first reported synthesis of 1-aza-norbornan-3-one (41a) commences with the condensation of
2-pyrrolidinone (44) with diethyl oxalate (43) to give the diketoester (45). This reaction proceeds via
N-acylation of 2,3-pyrrolidinone, ring opening of the imide and a Dieckmann cyclisation to give the
diketoester (45) which exists predominantly as the enol (46) [82]. Catalytic hydrogenation gives the
cis-hydroxy-ester which is reduced to the diol (48a). Thermolysis in the gas phase in a flow reactor
over basic alumina gave the alcohol (49) which was oxidised to 1-aza-norbornan-3-one (41a) with
Jones' reagent (62% yield) [83].
This synthesis has been re-examined recently. The ring expansion and reduction steps were
repeated in virtually identical yields to the original work. Ring closure using Mitsunobu reagents gave
a poor yield, however protection of the amine as the carbobenzyloxy derivative (48b) and selective
primary tosylation proceeded in virtually quantitative yield. Hydrogenolysis of the carbobenzyloxy
group and treatment with mild base effected cyclisation in excellent yield [84].
N 
H
CO2Et
O
O N 
H
CO2Et
OH
O
N 
H
CO2Et
OH
ON 
R1
OH
OR2
H2, Rh-alumina, AcOH (80%)
LiAlH4, THF
(66%)N
OH Basic alumina
310°C (33%)
N 
H
O
CO2Et
CO2Et KOEt, EtOH, Et2O
(90%)
(43)
(44)
(45) (46)
(47)
(48a) R1 = R2 = H 
(48b) R1 = Cbz; R2 = H 
(48c) R1 = Cbz; R2 = Ts 
(48d) R1 = H; R2 = Ts 
(49)
Cbz-succ, aq NaHCO3 
TsCl, pyr (97%, 2 steps) 
50psi H2, Pd-C
Ph3P, DEAD (33%)
 5h (89-99%, 2steps)
NaHCO3, 55-60°C
"Cyclodehydration" by thermolysis was also used in the synthesis of quinuclidinol (52).
Dihydroxylation of 4-vinylstyrene (50), pyridinium salt formation and catalytic hydrogenation gave the
4-(dihydroxyethyl)-piperidine (51) which was cyclised as before [85]. Although this sequence is brief it
suffers from two poor steps. The 35% yield for permanganate oxidation is adjusted for recovered
starting material and the apparently poor yield for hydrochloride formation is due to the use of crude
material from the prior permanganate oxidation.
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N
OH
(52)
N N 
H
OH
a KMnO4, 3°C (35%) 
b aq HCl (54%, 2 steps) Basic alumina, 300°C
(32%)c H2, PtO2, 4h (64%)
(51)(50)
HO
Thermal cyclodehydration was also used to prepare quinuclidinone (41b). 4-Pyridine-
carboxaldehyde ketal (54) was alkylated by formaldehyde via the quaternary aminol and the enamine
[86]. Catalytic hydrogenation gives the piperidine ketal (56), which was benzylated on nitrogen and the
ketal removed. Cyclodehydration was achieved under comparatively mild conditions by refluxing in
acetophenone (bp 202°C) [87].
All of the syntheses described thus far (with one exception) have used an archaic thermolytic
cyclodehydration to create the bicyclic ring system. In the following three contemporary examples,
displacement of a bromide or a sulfonate ester by the ring nitrogen is the key cyclisation step.
Nevertheless in the next synthesis the carbon skeleton is assembled in a similar way to the older work.
Catalytic hydrogenation of the pyridine monoester (58) gave the cis-product (59a) which was
protected as the t-butoxycarbonyl derivative (59b). Reaction of the acid chloride with diazomethane
gave the diazoketone (60) which was displaced to give the α-bromoketone (61).
N
O
(53)
N
O
(54)
H Bn
a PhCOMe,=∆=(45%)
b H2, Pd-C, EtOH, 
35min (85%)
N
CHO
N
OO
N
(CH2O)n, 175°C
(25%)
HO OH
PhH, ∆ (86%)
 HCl
N 
H
H2, Rh-C, H2O, 
25°C (87%)
HO
a BnCl, Na2CO3, 
EtOH,=∆ (92%)
(55)
(41b)
(57) (56)
HO
O
O
O
O
b conc HBr, 25°C 
(90%)
HO
The final cyclisation could be only be achieved in fair yield under high dilution conditions using
Hunig's base. The ratio of the products (62):(63) implies that cyclisation occurs predominantly with
retention of stereochemistry at the ring carbons bearing the carbonyl substituents, although clearly there
are other explanations for the stereoselectivity observed [88].
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(60)
(63) (61)
CO2Me CO2Me
HCl
N2
O
CO2Me
CO2Me
Br
OCO2Me
N
CO2Me
O
H2, PtO2
(Boc)2O, Na2CO3, 
aq dioxane (84%)
a NaH, THF; 
b SOCl2, THF,=∆
c CH2N2 (72%)
HBr, 
AcOH, 
CH2Cl2
(54% for 2 steps)
iPr2NEt, MeCN, ∆
 MeOH (100%)
1:9
(62)
There are few enantioselective routes to 1-azanorbornanes and quinuclidines because they are
comparatively easy to resolve as diastereomeric salts or by chiral HPLC. Moreover medicinal chemists
usually require both enantiomers for testing. The following synthesis illustrates the enantioselective
transacylation of a prochiral diol in organic solvent catalysed by a lipase. The prochiral diol (66c) was
assembled by aldol condensation of Meldrum's acid (64) with 4-N-benzylpiperidone (65), reduction of
the alkene, cleavage of the benzyl and acetal protecting groups (with esterification), reprotection of the
amine and reduction of the diester. Acetylation yielded the prochiral diacetate (66b) which was
hydrolysed by porcine pancreatic lipase (PPL) or a variety of other lipases to give the (S)-hydroxy-
acetate (66a) with low enantioselectivity (best result, 39% yield, 74%ee). The converse reaction;
irreversible acetylation of the diol (66c) with vinyl acetate (as solvent) gave the (R)-hydroxy-acetate
(66d), hence in both cases the enzyme is selective for reaction at the (pro-R)-group [89]. After routine
functional group manipulations, the mesylate underwent intramolecular nucleophilic displacement to
give (R)-3-hydroxymethylquinuclidine (R)-(42b) without erosion of enantiomeric excess [90].
N
O O
O O
N 
Bn
O
a Pyr, rt, 48h (89%); 
b H2, Pd-C, MeOH, rt, 12h (92%); 
c HCl, MeOH, ∆, 1h;
d CbzCl, aq NaOH, 0°C (95%); 
e NaBH4, LiCl, EtOH, rt (83%)
N 
Cbz
OR2R1O
OH
(66a) R1 = H; R2 = Ac 
(66b) R1 = R2 = Ac 
(66c) R1 = R2 = H 
(66d) R1 = Ac; R2 = H 
(66e) R1 = Ac; R2 = Ms 
(66f) R1 = H; R2 = Ms
PPL, H2O, 19h (39%, 74%ee) 
Ac2O, Et3N, DMAP, CH2Cl2, rt, 30min (90%) 
PPL, vinyl acetate, 23h (52%, >98%ee) 
MsCl, Et3N, CH2Cl2, -30°C, 5min 
LiOH, THF, H2O, rt, 6h
a H2, 10% Pd-C, AcOH, EtOH, rt
b Li2CO3, CH3CN,=∆, 2h (60%, 4 steps)
(R)-(42b)
(64)
(65)
H
H
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Despite spectacular advances in asymmetric synthesis, sugars continue to be important starting
materials for the synthesis of enantiomerically pure natural products [91, 92, 93] such as marine toxins
[94] and pheromones [95]. Two syntheses of (3S,5S)-quinuclidin-3,5-diol (73) demonstrate the use of
carbohydrates in the synthesis and demonstrate the pitfalls of extrapolating well known chemistry. The
first synthesis which proceeded as expected, commenced with D-arabinose dithioacetal (67a), which
was selectively protected at the 6-hydroxy group, the thioacetal cleaved and the furanose protected as
the 1,2-O-isopropylidene derivative (68). Oxidation yielded a ketone which reacted unusually rapidly
with a stable phosphorane, presumably due to the adjacent electron withdrawing groups. Manipulation
of the two carbon appendage gave an azido-furanoside (70c), which was hydrolysed to the azido-
pyranoside (71).
N
O
HO
OSitBuPh2
O
ORO SEt
SEt
OH
OH
OH
(67a) R = OH 
(67b) R = OSitBuPh2
tBuPh2SiCl, imidazole, 
DMF (95%)
b CuSO4, Me2CO (71%)
O
OSitBuPh2
O
O
CO2Me
a PCC, 3Å MS, CH2Cl2;  
b Ph3P=CHCO2Me, PhH, 
∆, 4h (81% for 2 steps)
a HgO, HgCl2, Me2CO; 
a H2, Pd-C, 
EtOAc, 2d
(100%); 
b LiAllH4, THF 
(88%)
O
N3
OHHO
HO
N 
Cbz
OR
HO
HO
H
(72a) R = H 
(72b) R = Ms
O
OSitBuPh2
O
O
(70a) X = OH 
(70b) X = OMs 
(70c) X = N3
(68)
(69)
MsCl, pyr (98%)
NaN3, DMF (96%)
H2O (80%)
OH
HO
 b NaOAc, EtOH, 70°C, 12h (78%)
a H2, Pd-C, aq MeOH  
b CbzCl, aq Na2CO3 
(77%)
MsCl, pyr (87%)
a H2, Pd black, EtOH
(71)
XCF3CO2H
(70)
(73)
6
6
Hydrogenation gave an amine which underwent reductive amination with the aldehydic form of the
lactol to give the piperidine which was protected as the carbobenzyloxy-derivative (72a). Selective
mesylation of the primary hydroxyl group (72b) and hydrogenolysis, followed by intramolecular
nucleophilic displacement gave (3S,5S)-quinuclidin-3,5-diol (73).
Functional analysis of this synthesis reveals that the strategy amounts to the appendage of a two-
carbon side chain to a pair of electrophiles (74). C-1 is engaged in the first ring forming step at the
aldehyde oxidation state and C-5 as the mesylate in the second ring forming step. A logistical
alternative would be to form the first ring by displacement at C-5 and then form the second ring by
displacement at C-1. This seemingly trivial modification resulted in unexpected results.
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1
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4
5
(74)
The C-5 hydroxyl group was unmasked by cleavage of the silyl ether and converted to the mesylate.
Reduction of the azide, intramolecular nucleophilic displacement and protection yielded the tricycle
(75). Cleavage of the sugar ring yielded the triol (76a), which was selectively mesylated at the primary
hydroxyl group which was formerly C-1 of the sugar. Hydrogenolysis of the carbobenzyloxy group
gave the tetrahydrofuran (77) as the major product in an inseparable mixture with the desired
quinuclidine (73). This result is in stark contrast to the cyclisation of the epimeric alcohol (72b) which
exclusively gave the quinuclidine (73). Direct protection of the diol (76b) as the bis(benzyl ether) (79)
was not possible and an alternative more circuitous route via the dithioacetal (78) had to be employed
[96-97].
O
X
O
O
Bu4NF, THF  
(95%) 
MsCl, pyr 
(94%)
a H2, Pd black, EtOH; O
O
O
CbzNb CbzCl, NaHCO3 (96% yield)
(70c) X = OSitBuPh2
(70d) X = OH 
(70e) X = OMs
N 
Cbz
OH
OR
HO
H
MsCl, pyr 
(81%)
(76a) R = OH 
(76b) R = OMs
N 
H
O
H
HO
N3
a aq AcOH; 
b NaBH4, EtOH  
(82%)
H2, Pd black, EtOH or
N
OH
HO
a NaOAc, EtOH (84%); 
b H2, Pd black, EtOH (88%) N 
Cbz
OBn
CH(SEt)2BnO
H
a aq CF3CO2H, 
EtSH (89%); 
b BnBr, NaH,  
Bu4NI (70%)
N 
Cbz
OBn
BnO
H
OR
c H2, Pd black, AcOH, 
EtOH, 2d (98%)
a H2, Pd-C, EtOH, 1d; 
b NaOAc, 60°C, (78%)
a HgCl2, HgO, Me2CO; 
b NaBH4, EtOH (88%) 
c MsCl, pyr (99%)
(75)
(78)
(79)(73)
(77)
Similar methodology was also employed in the synthesis of (S)-quinuclidinol [98-99] and the
meso-compound, (3R*,5S*)-quinuclidin-3,5-diol [100]. In each case in the second ring closure where a
hydroxy group was orientated cis to the side-chain bearing a terminal mesylate [cf (70b)],
tetrahydrofuran formation was faster than quinuclidine formation, whereas when they were orientated
trans  [cf (72)] quinuclidines were formed exclusively.
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CO2Et
TFA, CH2Cl2
 a aq K2CO3; b H2, Pd-C, 50°C, 6h; c aq K2CO3
N 
Bn
OMeMe3Si
EtO
O
N
Br
H Bn
 (56%)
HBr, EtOH
(80)
(81) (82) (83)
(56%)
(84)
In most syntheses of 1-aza-norbornanes a piperidine ring is constructed first and the ring system is
completed by cyclising the "one carbon bridge". This approach benefits from the rich chemistry of
pyridines and the ease by which they can be reduced to piperidines. The following two syntheses utilise
the alternative approach in which a two carbon bridge is constructed between positions 1 and 3 of a
pyrrolidine.
Treatment of N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine (81) with trifluoro-
acetic acid generates an iminium ylide [101] which undergoes 1,3-dipolar cycloaddition to the
unsaturated pyrone (80). Cleavage of the lactone ring with hydrogen bromide in ethanol, gives the
bromoester (83) which upon treatment with base cyclises and benzyl group hydrogenolysis gives the
endo-ester (84) [102-103]. The same cycloaddition to 3-exo-methylene-butyrolactone provides access
to 4-substituted 1-aza-norbornanes [104-105].
1,2,4-oxadiazoles have long been used as metabolically stable analogues of carboxylic acids, esters
[106] and amides [107], but it is less widely appreciated that an alkyl group at C-5 has acidic properties
which are comparable to an ester. The trimethylammonium salt (87b) was conceived as a minimalist
analogue of the muscarinic receptor "super agonist", L-690,548 (91) [108]. The heterocycle (87a) was
constructed by conventional means and methylated to give the trimethylammonium salt (87b). At pH
7.4 in water this had a half life of only 45 minutes and treatment with mild base enabled the alkene
(88) to be isolated. This suggested that the trimethylammonium compound (87b) might be usable as an
electrophilic synthon for substituted 5-ethyl-1,2,4-oxadiazoles. Treatment with a range of nucleophiles
under basic conditions enabled the preparation of sundry amines, the benzyl thioether (87c) and the
ether (87d). Substitution with 3-hydroxypyrrolidine (89), mesylation, treatment with potassium t-
amyloxide to give the α-1,2,4-oxadiazole anion and intramolecular nucleophilic substitution
expeditiously yielded L-670,548 (91) in 21% yield for the entire sequence [109]. The exo:endo ratio
(86:14) is probably not a function of the orientation of the mesylate group, because in another synthesis
of this target a 90:10 ratio was observed also under basic conditions [110]. Hence the ratio reflects a
thermodynamic mixture formed by equilibration of the α-1,2,4-oxadiazole anion.
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N
NO
N
(87a) X = Me2N 
(87b) X = Me3N 
(87c) X = BnS 
(87d) X = MeO
H2N
NHO
(39% yield)
NaH, THF
N
N
O
N
N
O
R
N
N
O
N
(91) L-690,548
RO
(90a) R = OH 
(90b) R = OMs
MeI, acetone 
(90% yield)
NaH, MeOH, ∆,  
3h (80% yield)
BnSH, iPr2NEt,=∆, 
48h (84% yield)
H 
N
HO
 iPr2NEt, 20°C, 
(97% yield)
(88)
(89)
CO2Me
Me2N
MsCl, pyr, rt (88% yield)
KOCMe2Et, THF, rt
(65% yield; 86:14, exo:endo)
aq NaHCO3 
(90% yield)
(85)
(86)
5.3.2 Dieckmann Condensation
In work described as the synthesis of "spasmolytically active esters" quinuclidone (41b) was
prepared by a Dieckmann condensation (intramolecular Claisen condensation). The carbon skeleton
was assembled by alkylation of methyl isonicotinate (92) with ethyl bromoacetate, which facilitated
reduction to the piperidine (93). The cyclisation was achieved using molten potassium in toluene which
was reported to give superior yields to sodium [111]. This sequence was repeated using potassium
ethoxide as the base for the Dieckmann cyclisation [112] and extended to the ester (96), by formation
of the cyanohydrin (94), methanolysis to the α-hydroxyester and elimination to the alkene which was
hydrogenated [113].
N
O
N
CO2Me
a BrCH2CO2Et, EtOH;
N
CO2Me
CO2Et
b H2, PtO2, 6h  
(75% for 2 steps)
a K, PhMe,=∆; b iPrOH
c conc. HCl; d aq KOH 
(~40%)
N
OH
CN
N
CO2Me
a conc HCl; 
b aq KCN 
(95%)
b H2, PtO2, 
rt, 17h
a SOCl2,=∆,  
24h (72%);
(92) (93) (41b)
(94)(96)
N
CO2Me
(95)
OH
a conc HCl,  
20°C, 48h;
b MeOH, 
20°C, 48h 
(77%);
The methyl derivatives (98) (101) gave an unexpected result. The cis-isomer (98) was prepared as
above and the trans-isomer (101) by base catalysed epimerisation. The structure (101) depicted in the
scheme is the enantiomer of the epimer produced by epimerisation of the cis-methyl ester (100). This
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enables the products (99) (102) to be compared more easily. Treatment of both the cis- and trans-
isomers (98) (101) with base gave almost exclusively the anti-methyl-quinuclidinone (102) (>96%).
This presumably indicates that cyclisation syn to the methyl group is disfavoured, although this does
not preclude a rationalisation in which deprotonation adjacent to the 4-ester group is faster for both
stereoisomers than cyclisation [114].
N
CO2Me
N
CO2Me
N
CO2Me
N
CO2Me
CO2Me
O
b H2, Pd-C, 
MeOH (60%)
b BrCH2CO2Me, 
K2CO3,PhMe, 
60°C (95%)
N 
H
CO2Me
N
O
HCl, H2, PtO2, 
AcOH (88%)
a NaOMe, MeOH, 
∆, 48h (68%);
a BrCH2CO2Et,  
MeOH, ∆;
(97)
(98)
(99)
(100)
(101)
(102)
a KOtBu, PhMe,=∆
b conc HCl,=∆
(42%, de >92%)
The hydrogenation of pyrroles is much more difficult than that of pyridines, consequently a
different approach must be used for the synthesis of 1-aza-norbornan-3-one (41a). Methyl glycinate
(104) presumably undergoes sequential Michael addition and acylation with dimethyl itaconate (103)
to give the 2-pyrrolidinone (105). The alternative sequence consisting of acylation followed by
cyclisation would require a disfavoured 5-endo-trig Michael addition. Interestingly the diester (105)
did not undergo Dieckmann cyclisation presumably because of the rigidity imparted by amide
resonance. Selective reduction of the amide in the presence of a pair of esters gave the pyrrolidine
analogue (106) of the piperidine (93) which underwent Dieckmann cyclisation in slightly better yield.
The ketone (41a) was homologated to the corresponding exo-ester (109) by Peterson olefination with
the anion derived from 2-trimethylsilyl-1,3-dithiane (107) and methanolysis [115-116].
N
O
CO2Me
MeO2C
CO2Me
H3N
N
CO2Me
CO2Me
O
NaOMe, MeOH
b aq K2CO3, ∆∗
(40%)
a KOtBu, PhMe, 140°C, 4h; 
b conc HCl, ∆ (65%)
N
CO2Me
CO2Me
∆, 16h
a BH3.THF, ∆;
N
CO2Me
S
S
Me3Si
nBuLi, -35 to 
20°C (100%)
55°C, 4h N
S
S
MeOH, HCl,
(105) (106)(104)
(103)
(41a)(109) (108)
(107)
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The use of a directed elimination is essential for this homologation as the following sequence
illustrates. Formation of the cyanohydrin (110), hydrolysis and esterification gave the hydroxy-ester
(111) in a sequence [(94)(95)] identical to that employed for quinuclidinone (41b). However treatment
of the exo-alcohol (111) with diethylaminosulfur trifluoride (DAST) gave the nortricyclene (112) in
76% yield via the norbornyl cation The endo-alcohol (111) gave the same product in 40% yield. This
of course results from the better overlap of the 4,5 carbon-carbon bond with the anti-bonding orbital of
the departing sulfur trifluoride derivative when it is in the exo-position.
N
O
N OH
CN
N OH
CO2Mea conc HCl;
DAST, CH2Cl2, -78°C
(41a)
N
CO2Me
aq NaCN
b MeOH, HCl
(exo-OH 76%; endo-OH 40%)
(110) (111)
(112)
N
(113)
The pKa's for quinuclidine, 1-azanorbornane and 4-azatricyclo[2.2.1.02,6]heptane (113) are 10.8,
10.5 and 9.0, respectively. Ring strain increases the p-orbital composition of the intra-annular bonds,
which increases the propensity to accept electron density from the lone pair [117]. These comparatively
small differences in pKa's have a big impact on penetration of the blood-brain barrier, which rejects
quarternary ammonium salts. The diester (106) has also been prepared by 1,3-dipolar cycloaddition to
methyl acrylate (114), alkylation by ethyl bromoacetate and benzylic hydrogenolysis [118].
TFA, CH2Cl2
N 
Bn
OMeMe3Si
CO2Me
N 
Bn
CO2Me
N
CO2Me
CO2Me
a BrCH2CO2Et, 
EtOH, K2CO3 
b H2, Pd-C; 
c K2CO3  (59%)
(115)
(114)
(116) (106)
Enantiomerically pure ketone (41a) and ester (109) have been prepared in two ways. Racemic 1-
aza-norbornan-3-ol (49) was resolved by crystallisation of the tartaric acid salts and Swern oxidation
gave the ketones (41a) which were homologated to the esters (109) by the Peterson dithiane sequence
described above. The absolute configurations were determined from circular dichroism spectra and
measurements of X-ray crystallographic anomalous dispersion [119]. The ester (109) has also been
resolved by column chromatography of the diastereomeric carboxamides (119) and the absolute
configuration determined by X-ray crystallography. Protection of the tertiary amine as a borane
complex was required to prevent decomposition during purification and remarkably this survived
alkaline hydrolysis and mixed anhydride formation. It was ultimately cleaved by refluxing in
concentrated hydrochloric acid [120]!
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N
CO2Me
rac-(109) 
(R,R)-(109)
N
CO2R
BH3
N
BH3
N
O
H
R
BH3, THF, -78°C (73%)
aq NaOH, 
MeOH (77%)
iBuO2CCl
H2N R
Silica gel chromatography 
(R,R,R)-(119) 17%, 96%de; 
(S,S,R)-(119) 26%, 98.8%de
a conc HCl,=∆
(117a) R = Me 
(117b) R = H
(S,S)-(109)
b SOCl2, MeOH
(51%?)
(51%)
(R)-(118)
5.3.3 Ester Surrogates
Work at the Merck Neuroscience centre in the UK directed towards developing 1,2,4-oxadiazole
derivatives of 1-aza-norbornanes (120) and quinuclidines (121) resulted in some extremely potent
compounds. Some of these compounds have been reported earlier in this review (cf. Central nervous
system). Their structures are repeated here for convenience.
N
NO
N R
(120a)= (91) R = Me; L-670,548 = 91 
(120b) R = NH2; L-670,207
(120c) = (14) R = cyclopropyl; L-687,306 
(120d) R = alkyl
H2N
N
HO
R
NaOEt, EtOH, 4Å  MS,=∆, 4hN
CO2Me
(109)
N
NO
N R
(121a) R = Me; L-658,903 
(121b) R = NH2; L-660,863
All four stereoisomers of the 3-methyl-1,2,4-oxadiazole (91 = 120a) were prepared individually
using the borane carboxamide resolution described above, plus base catalysed epimerisation to access
the endo-diastereoisomers. Both of the exo-diastereoisomers had identical predicted cortical efficacy
and were full agonists at the muscarinic receptor based on the displacement of [3H]-oxotremorine-M
and [3H]-scopolamine. Moreover the (3R,4R)-exo-stereoisomer (91 = 120a, actual structure depicted)
had a ten fold higher affinity. The exo-stereoisomers were full agonists at M1, M2 and M3 receptors in
three tissue preparations and the (3R,4R)-exo-stereoisomer (91 = 120a) had some potency selectivity
for the M2/M3 receptors over M1 [121]. It also had excellent brain penetration; 3.8 % of the
administered dose entered the CNS, which is comparable to the percentage of the weight of the mouse
brain relative to body weight (2-5%) Increasing the hydrogen bonding capability of the 1,2,4-
oxadiazole by replacing methyl with amino (120b) improved the efficacy by increased binding to the
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agonist state of the receptor, but this was offset by a reduction in CNS penetration (0.24%). The 1-aza-
norbornanes (120a,b) and the quinuclidines (121a,b) had up to a 1000 fold higher affinity than
arecoline (33b). They also produced peripherally mediated salivation and centrally mediated
hypothermia at doses 50-50,00 fold lower than arecoline (33b). The methyl derivative (91 = 120a) is
particularly noteworthy, it produced hypothermia at does of 0.0016mg/Kg making it one of the most
potent CNS active muscarinic agonists known [121-122]. These properties make these compounds
useful research tools, but are the exact opposite of those required for treating conditions such as
Alzheimer's disease.
In general for these compounds as the size of the 3-substituent on the 1,2,4-oxadiazole ring (120d)
increases, the efficacy decreases and 3-alkyl chains which are longer than n-propyl confer antagonist
properties. The cyclopropyl derivative (14 = 120c) only has limited selectivity in binding assays, but is
a partial agonist in M1 and an antagonist in M2 and M3 tissue assays [123-124]. In tissues with a large
receptor reserve a partial agonist is sufficient to elicit maximal effects and is more likely to be show
receptor selectivity and hence minimise side effects. This prompted a search for compounds with lower
efficacy.
The pyrazine, L-680,648 (126) was assembled by fairly standard methodology. In this case
substitution of the hydroxyl group does not result in elimination or non-classical norbornyl cation type
rearrangements, because the hydroxyl group is in the endo-position and carbonium character is
stabilised by the pyrazine ring. The endo-adduct (125) was easily epimerised to the exo-adduct (126) by
base treatment, due to stabilisation of the carbanion by the pyrazine ring. The pyrazine (126) had an
affinity and predicted cortical muscarinic efficacy comparable to that of the extremely potent 3-amino-
1,2,4-oxadiazole (120b). In general quinuclidines have lower muscarinic activity than the
corresponding 1-azanorbornanes. Amongst a huge range of compounds the chloropyrazine emerged as
a ligand with useful properties and was prepared via two routes.
N
O
N
OH
(41a)
N
N
N
Cl
N
N
N
H
N
N
N
N
I
tBuLi, Et2O, 
-45°C (30%)
SOCl2, CH2Cl2, 0°C
H2, Pd-C, MeOH
N
H
N
N
(endo:exo 10:1)
(endo:exo 10:1)
NaOMe,=∆, 2h
(126) L-680,648
(123)
(124)
(125)
(122)
Molecules 2001, 6 172
The enolate of the ester (96) was alkylated by 2,6-dichloropyrazine (127) and decarboxylated by
treatment with conc hydrochloric acid. Presumably the proximal nitrogen acts in the same way as a
ketone in a β-ketoacid and the reaction goes via an enamine [125-126]. This procedure was deemed
impractical on a large scale due to the high costs of the quinuclidine derivative (96) and the low
temperature for the alkylation.
N
CO2Me
rac-(96)
N
N
NCl Cl
N
N Cl
(15) L-689,660
R
N
CO2Me
N
N Cl
BuLi, Et2O, -50°C (60%)
a conc HCl, 130°C, 3h
b (+)-Di-O-,O'-p-toluoyl-L-tartaric  
acid, EtOH (99.2%ee); c EtOH,=∆
(128)
(127)
In the second, more practical synthesis, 4-piperidone (129a) was protected and converted to the
α,β-unsaturated ester (130) by reaction with a Horner-Wittig reagent. Alkylation of the ester enolate
with 2,6-dichloropyrazine (127) completed the carbon skeleton and the ester was hydrolysed to the acid
to enable resolution with α-methylbenzylamine. Reduction of the enantiomerically pure acid (132b) to
the alcohol (133a) with borane-tetrahydrofuran complex, mesylation and cleavage of the t-
butoxycarbonyl group revealed the amine, which displaced the mesylate to give the chloropyrazine, L-
689,660 (15) [127].
N
N 
R
O
N 
Boc
CO2Et
N 
Boc
CO2Et
N 
Boc
CO2R
N
NCl
N
NCl Cl
N 
Boc
N
NCl
N
N Cl
OR
(Boc)2O, aq 
NaHCO3 (100%)
K2CO3, DMF (97%)
aq  NH4HCO2, Pd-C
H H
EtOH (98%)
(129a) R = H 
(129b) R = Boc
(EtO)2POCH2CO2Et
NaN(SiMe3)2
MsCl, Et3N, 
EtOAc (100%)
(133a) R = H 
(133b) R = Ms
Ph NH3
(132a) R = Et 
(132b) R = H 
(132c) R = 
aq NaOH, 
EtOH
(41.5%) aq HCl
a HCl, EtOH; 
b aq K2CO3 (61%)
BH3.THF (57%)(15) L-689,660
R
S
(130) (131)
(127)
Molecules 2001, 6 173
L-689,660 showed no muscarinic receptor subtype selectivity in binding assays, but in
pharmacological tissue assays it was a potent M1 and M3 agonist and a M2 antagonist [128]. This
selectivity is presumably due to the low intrinsic activity that confers the ability to exploit differences
in effective receptor reserve. It was capable of crossing the brain-blood barrier and was active in
several rat behavioural studies. For example it reversed a scopolamine (11) induced performance
deficit [129].
N
(134a)
R O
N
R CN
N
OMe
 
b NaCN, DMSO, 95°C, 5h 
(60% yield)
H OMe a Ph3P, CCl4, CH3CN, ∆, 5min 
(61% yield, Z:E 5:1)
(134b) Sabcomeline, SB-202026
R Z
= R
As noted above oxime derivatives of arecoline (35) (36) are potent agonists. Similarly the imidoyl
nitrile, sabcomeline, SB 202026 (134b) is a highly potent muscarinic partial agonist that exhibits
functional selectivity for effects mediated by M1 receptors [130].
The preparation was very simple. The N-methoxycarboxamide (134a) was converted to the imidoyl
chloride which was substituted by cyanide to give a 5:1 mixture of E:Z geometric isomers which were
separated by column chromatography. The (Z)-stereoisomer was resolved by sequential salt formation
with (R)-(-)- and (S)-(+)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphate and the absolute configuration
determined using X-ray crystallographic anomalous dispersion measurements [131-132]. Sabcomeline
(134b) caused a significant improvement in a visual object discrimination task in non-cognitively
impaired marmosets without side effects [133] and improved performance in a maze task by rats [134].
It is currently in phase III clinical trials
The propargyl oximes (137b) provide a neat solution to the problem of maintaining agonist activity
whilst adding functionality to obtain selectivity The functional group is placed at the end of a long
alkyne boom so that it does not interfere with critical receptor binding, but can interact selectively with
other portions of the receptor. O-Substituted hydroxylamines were prepared by conventional alkylation
of N-hydroxyphthalimide (135a) with allyl and propargyl bromides or by a Mitsunobu type
displacement of the corresponding alcohols [135], followed by N-methylhydrazine cleavage of the
imide.
The oximes were formed as a mixture of (Z) and (E)-stereoisomers, which were separated by HPLC
[136,137,138]. The (E)-isomers had weak or no muscarinic activity compared to the (Z)-isomers and
the most selective compound was the (R)-enantiomer of the 3'-methoxyphenylpropargyl derivative
(138) (CI-1017), which had good selectivity for m1 receptors over m2 [139].
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N
N
O
OMeZ
N
O
O
OR
(135a) R = H 
(135b) R = substituted allyl or propargyl
RBr, K2CO3, DMSO, rt or 
ROH, DEAD, Ph3P, THF, rt 
H2N-NHMe
H2N OR
N
N
OR
THF, CH2Cl2, rt
N
O
(138)
(41a)
(136) (137)
R
6 Muscarinic Antagonists
Muscarinic antagonists are generally bulkier molecules than agonists and they embrace a much
wider range of chemical structures. A tertiary amine is more or less obligatory and most contain an
aromatic moiety, but classification within these broad boundaries is difficult. Consequently within this
section methods of synthesis and metabolism are exemplified rather than SARs.
6.1 Enantioselective Synthesis of Tertiary Centres; Tolterodine, Rociverine, IQNP
Tolterodine (27a) is a fast acting treatment for urge incontinence(UI, see Urinary bladder) [140]. It
inhibits urinary bladder contraction, without inhibiting salivation, a phenomena which cannot be
explained in terms of selectivity for a single muscarinic receptor subtype [141] (cf. Urinary Bladder).
In mice, dogs and humans the predominant metabolic pathway for tolterodine is hydroxylation of the 5-
methyl group by CYP2D6 (cytochrome P450 2D6)[142], followed by oxidation to the aldehyde and
carboxylic acid. N-dealkylation by CYP3A was a minor pathway [143].
N
HO
O N
OO
Ph
Ph
BnO
O N
OO
Ph
BrMg
BnO
R
Ph
R
CuBr-Me2S, THF 
(98% ee, 84% yield)
a LiOH, H2O2, aq THF  (90% yield); 
b SOCl2, pyr, PhH; 
c iPr2NH (81% yield); 
d LiAlH4, Et2O;  
e Pd-C, H2, MeOH (74% yield)
R
(27a) R = H; (+)-Tolterodine 
(27b) R = OH; 5-Hydroxy-tolterodine
CYP2D6
(137) (138)
R R
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5-Hydroxy-tolterodine (27b) has a similar pharmacological activity to that of the parent compound
[144-145] and hence CYP2D6 polymorphism has little effect on the anti-muscarinic activity [146].
Tolterodine (27a) and 5-hydroxy-tolterodine (27b) were detected at the pM to nM level in plasma by
capillary LC-MS with a sheathless electrospray source [147-148].
An asymmetric synthesis of Tolterodine (27a) utilises conjugate addition [149] of an aryl cuprate to
an Evans' [150] N-cinnamoyl oxazolidinone (137). A range of stereodirecting groups were surveyed
and although some gave marginally better stereoselectivity and yields (eg cis-4,5-diisopropyl and cis-
4,5-diphenyl), the commercial (4S)-oxazolidonine derived from (R)-phenylglycine (137) proved to be
the most practical alternative [151].
O N
OO
Ph
Ph
R
(137)
O N
OO
Ph
Ph
R
Mg
Br
Me
Cu
Me
O N
OO
Ph
Ph
R
Mg
Br
Me
(140)
O N
OPh
O
PhR
Mg
Br
Me
(141)
MeMgBr,
CuBr-Me2S
(139)
THF 253ºK
293ºK
A NMR investigation of this mechanism of the conjugate addition has revealed three intermediates.
The first is a π-complex of the cuprate reagent with the alkene (139) in which the two methyl groups
can be distinguished. After methyl transfer two rotomers are present. The coordinated enolate (140) is
more stable at lower temperatures, whereas the non-coordinated enolate (141) is formed at higher
temperatures, which has a substantial effect on the stereoselectivity of reactions with electrophiles
[152].
Rociverine (Rilaten) (145) is a useful antispasmodic with neurotropic and myotropic properties
used to treat urge incontinence and nocturia in the elderly. Commercial rociverine is a mixture of four
diastereoisomers with a cis-relationship between the hydroxy and carboxylic substituents on the
cyclohexane ring. The cis-(1S,2S)-diastereoisomers have high selectivity for binding to m1 receptors,
whilst the cis-(1R,2R)-diastereoisomers are the most potent for all receptor (m1-m5) sub-types [153]. A
dicyclohexyl carboxylic acid synthon was assembled by Grignard addition and resolved using a lipase.
Addition of cyclohexylmagnesium chloride to 2-hydroxymethylcyclohexanone (142a) gave a mixture
of cis- and trans-diols (ratio 55:45) in poor yield. In contrast the methoxy-isopropyl acetal (142b) gave
exclusively the cis-isomer in excellent yield, with the protecting group being removed during work-up.
The hydrophobic diol rac-(143) was resolved by pig pancreatic lipase (PPL) catalysed trans-acylation
with vinyl acetate in t-butyl methyl ether [154]. This reaction is irreversible because the vinyl alcohol
Molecules 2001, 6 176
readily isomerises to acetaldehyde, however it slowly deactivates enzymes by reaction with basic
amino acids such as lysine. At 72% conversion the enantiomeric excess of the residual diol was
maximised (1R,2S-143, 85%ee), whereas at 28% conversion the enantiomeric excess of the
monoacetate was maximised (144, 78%ee) [155] at the expense of poor yields in both cases.
Consequently in subsequent work, the rociverine (145) was resolved by diastereomeric salt formation
with tartaric or di-O-benzoyl-tartaric acid [156].
O
O
N
Et
Et HO
(145) (1S,2S,3RS)-Rociverine
HOOR
O
OMe
(142a) R = H
(142b) R = 
HO
SS SR
OAc
a cC6H11MgCl; b aq HCl
HO
AcO
(R = H, 58%; R = MIP, 96% yield)
PyHOTs, 
0°C, 5min
rac-(143)OMe
PPL, TBME, 
27°C, 16h
(144)
(MIP)
The imaging of the location of muscarinic receptors is a rapidly developing field [157]. Older
techniques such as autoradiography are in many cases being supplanted by positron emission
tomography (PET) [158-159] and single photon emission computed tomography (SPECT) [160,161,
162]. These techniques rely on ligands [163] which bear radiolabels with a short half-life (eg 11C, 18F
[164], 76Br, 99mTc or 123I). Consequently not only must the ligand be able to bind to the receptor
selectively, but it must have a precursor which can be used to attach the radiolabel quickly, in high
radiochemical yield and with minimum purification. For example, the substitution of vinylstannanes by
iodine-123 (or 125I) has emerged as a standard technique, because it can be accomplished in just 5
minutes [165].
The iodoalkene IQNP (151b) has been developed as a SPECT imaging agent modelled on
quinuclidinyl benzilate. It localises in the brain at the sites of Ach receptors and has some selectivity
for the muscarinic receptor subtypes.
An enantioselective synthesis has been developed using Seebach's 1,3-dioxolanone method for the
α-alkylation of α-hydroxyl-carboxylic acids [166]. Condensation of pivaldehyde and (S)-mandelic
acid, remarkably gives predominantly the cis-diastereoisomer (147). Deprotonation destroys the
original stereocentre of the mandelic acid, but the t-butyl group attached to the acetal directs alkylation
of the enolate to the other face to give the propargyl derivative (148). Overall this amounts to
alkylation with retention of configuration [167]. The carboxylic acid (149b) has also been resolved via
the α-methylbenzylamine salt [168]. The (E,3R,1'R)-stereoisomer (151b) binds selectively to the m1
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receptor subtype, whereas the (Z,3R,1'R)-stereoisomer binds to both m1 and m2 receptor subtypes
[169].
N
O
O
R
(151a) R = SnBu3
(151b) R = I
N
ONa
O O
O
OH
O O
OR
RCO2HHO
(98% cis by GC, 
82% yield)
tBuCHO, pTsOH, 
H2SO4, pentane,=∆
Br
a aq NaOH, MeOH;
b EtOH, conc H2SO4
R
LiN(SiMe3)2
THF, -78°C to rt, 3h
EtO
O
OH
a
b Bu3SnH, AIBN
I2, CHCl3
R
R
R
(146) (147) (148)
(149a) R = H 
(149b) R = Et
(150)
6.2 Diels-Alder Reactions
One of the holy grails of enzymology is the determination of the structure of an enzyme capable of
catalysing Diels-Alder reactions [170]. Recently two cell free fractions from Alternaria solani have
been purified [171], which are capable of converting prosolanapyrone II (152a) to solanapyrones A
(153) and D [172], which can be rationalised as an oxidation followed by an intramolecular Diels-
Alder reaction [173-174]. In this section the application of Diels-Alder reactions in the synthesis of
muscarinics will be discussed, with particular emphasis on biomimetic Diels-Alder reactions.
O
OMe
O
R
(153) (-)-Solanapyrone A(152a) R = CH2OH, Prosolanapyrone II
(152b) R = CHO, Prosolanapyrone III
(51%, 99%ee, exo:endo 6:1)
O
OHC OMe
O
Diels-Alderase
H2O2
O2
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6.2.1 Indole Alkaloids; Allosteric Activators of Muscarinic Binding
N
N
OO
H
H
H
H
H
(154a) R = H; Strychnine
(154b) R = OMe; Brucine
R
R
Ac
N
H
N
H
Et
OMe
(155) Aspidospermine
N
NH
H
N H
H
H
H
OH
HO
N
(156) A lcuronium
Several naturally occuring indole alkaloids eg (154a) [175], (154b), (155), (156) [176] bind to the
five muscarinic receptor subtypes at allosteric sites. The binding of ligands at these sites increases or
decreases the binding of other ligands to the receptor. For example, brucine (154b) increases the
affinity of Ach (1a) about two fold at m1 receptors, N-chloromethyl-brucine three fold at m3 receptors
and brucine N-oxide 1.5 fold at m4 receptors [177]. Compounds with this activity would be valuable in
conditions such as Alzheimer's disease where Ach levels are decreased. Clearly strychnine (154a) is an
unlikely candidate as a medicinal entity! Lead compounds have the ring system of aspidospermine
(155) minus the bis(methylene)-bridge, plus the δ-lactam ring of strychnine (154a) and brucine (154b).
The Diels-Alder precursor (157) was prepared by condensation of N-benzylpiperidone with indole,
followed by acylation and conversion to the salt with hydrochloric acid.
The diene component (157) is slightly electron rich, whereas the dienophile is unactivated,
consequently high temperatures were required to effect cycloaddition. The initial adduct (158) with a
trans, trans-relationship between the bridgehead hydrogens was isolated after heating at 170°C for 5
days. Treatment with acid caused an overall [1,3]-hydrogen shift to give the indole (159), which could
also be accessed directly by cycloaddition-rearrangement at 240°C for 2 hours in a flow of argon.
These cycloadditions were run in open vessels or in a gas flow as indicated, so that the initial
N
N
O
N
N
O
H
H HMesitylene, 170°C, 5d
N
N
O
H
H
H
Ph2O, Ar stream, 240°C, 2h
(79% yield)
(74% yield)
HCl, EtOH, 150°C, 
1.5h (83% yield)
Bn
H
Bn
Bn
(157)
(158)
(159)
Molecules 2001, 6 179
hydrochloride salts were converted to the free amine substrate and/or product during the course of the
reaction.
N
N
O
N
N
O
a Ph2O, Ar stream, 240°C;
N
N
O
Ph2O, Ar, 240°C
Bn H
b HCl
H
Bn
H
N
N
O
H
Bn
N
N
O
H
H
Bn H
(160) (161)
(162)
(164) (165)
N
N
O
Bn
H (163)
H
H
 (94% yield)
 (94% yield)
Bn
The crucial role of these conditions was demonstrated in the cycloaddition of the acetylenic diene
(160). When this was performed under a stream of argon the expected adduct (161) underwent 1,4-
elimination of hydrogen to give the piperidyl carbazole (163). Whereas under a static atmosphere of
argon, acid catalysed shift of the alkene bond gave the thermodynamically more stable enamine, which
underwent cycloaddition to give the 1,4-dihydrobenzene (164) and aromatisation by 1,4-elimination of
the protonated amine to give the 3-aminopropyl carbazole (165) [178-179].
6.2.2 Himbacine; A Muscarinic Antagonist with Allosteric Properties
O
N
O
H
HH
H
R
O
N
O
H
HH
(167) Himgravine(166a) R = H; Himbeline 
(166b) R = Me; Himbacine
Himbacine (166b) was first isolated from the bark of the Australian pine tree, Galbulimima
(Himantandra) baccata FM Bail in 1956. It has low toxicity and was initially used as an anti-
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spasmodic agent. It is a selective antagonist for the M2 and M4 muscarinic receptor sites [180] with
allosteric properties [181-182], which has led to proposals for its use in the treatment of Alzheimer's
disease [183] (cf. 2.6 Central nervous system for the mechanism). Analogue studies have shown that
removal of the carbonyl group reduces the selectivity for M2 receptor types 20-fold [184], whereas
replacement of the tricyclic moiety by dihydroanthracene increases the affinity for both M1 and M2
receptor types [185].
O
N
O
H
HH
(167) HimgravineO O
N
a [4+2]
b H
(168)
Baldwin has proposed that the dehydrodecalin rings of himgravine (167) are assembled
biosynthetically by an endo-selective intramolecular Diels-Alder cycloaddition of the tetraene
imminium salt (168) followed by reduction. A second reduction would then yield himbacine (166b).
Making a more pragmatic analysis; most synthetic routes to himbacine have utilised an
intramolecular Diels-Alder reaction which yields a progenitor of the exocyclic alkene bond. This
approach has the potential to correctly install five contiguous chiral centres directed solely by the C-11
methyl group. However contrary to this favourable prognostication, the cycloaddition of (E,E,E)-1,3,9-
decatrienes frequently occurs with low stereoselectivity, although this problem can be mitigated by an
electron withdrawing group attached to the dienophile.
R
O
O
O
O
HH
H
R
O
O
HH
H
R
110°C, 16h
(170) endo-anti
(171) exo-anti
(dr 1:1, 30% yield)(169)
O O(169a) R = CHO (170b), (171b) R =
Me3SiO OSiMe3
F3CSO3SiMe3, CH2Cl2, 
-78 to -20°C
(169a) R = CHO
(dr 40:1, 53% yield)
(dr 8:5:6:1, (170a):(171a):epi-(171a):epi-(171a), 85% yield)
(169c) R = COSEt (170c), (170c) R = COSEt
(170a), (171a) R = CHO
PhMe, 170°C, BHT, 24h
11
SiO2, Et2AlCl,  40°C, 96h
(dr 20:1, 75% yield)
(169c) R = COSEt (170c), (170c) R = COSEt
Treatment of the aldehyde (169a) with bis(O-trimethylsilyl)ethane diol and trimethylsilyl triflate
gave the corresponding acetal which under the acidic conditions gave the corresponding oxonium ion
analogous to the iminium ion postulated in the biosynthetic sequence. In situ Diels-Alder cycloaddition
then gave the desired product (170b) with excellent stereoselectivity. Evidence for the intermediacy of
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the oxonium ion was provided by experiments in which treatment of the isolated acetal with
trimethylsilyl triflate gave the same product, whilst treatment of the aldehyde (169a) with trimethylsilyl
triflate gave a mixture of three isomers [186]. In contrast thermal Diels-Alder cycloaddition of the
aldehyde (169a) required heating at 170°C and a mixture of four diastereoisomers were produced [187-
188]. Similarly thermal cycloaddition of the triene (169c) gave an equal mixture of the two
diastereoisomers (170c,171c) in low yield whereas the acid catalysed reaction gave predominantly the
desired endo-anti-stereoisomer (170c) [189-190].
O
N
O
Boc
O
N
O
H
H
Boc
HPhMe, 1% TEMPO
a DBU; 
b (Boc)2O, aq NaOH (60% yield); 
c H2, Raney Ni, MeOH (72% yield); 
d CF3CO2H, CH2Cl2;
(171) (172)
O
N
O
H
HH
H
R
(166a) R = H; Himbeline 
(166b) R = Me; Himbacine
180°C, 8h
HCHO, CH3CN, NaBH3CN (78% yield)
In a bold strategy, the tetraene (171) underwent an exo-selective Diels-Alder reaction to generate
the "central" cyclohexane. The stereochemistry adjacent to the carbonyl group was corrected by
treatment with base which also caused partial cleavage of the t-butoxycarbonyl protecting group.
Reprotection and hydrogenation effected reduction of the endocyclic alkene bond without affecting the
sterically encumbered exocyclic alkene bond. Acidic deprotection yielded himbeline (166a) and
reductive methylation himbacine (166b) in 11 steps and a remarkable overall yield of 9.7% from (S)-2-
methylpiperidine L-tartrate [191].
6.2.3 Cyclostellettamines; Macrocyclic Muscarinic Antagonists
N
N
β
α
(173) Cyclostellettamines
 
(173a) 
(173b) 
(173c) 
(173d) 
(173e) 
(173f)
a
10 
10 
11 
10 
11 
12
b
10 
11 
11 
12 
12 
12
 
A 
B 
C 
D 
E 
F
Some thirty 3-alkylated-polypyridines have been isolated from marine sponges (order
Haplosclerida) [192-193]. Many of these are potent anti-bacterials and cytotoxins. The
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cyclostellettamines (173a-f) are bispyridinium macrocycles isolated from the marine sponge Stelletta
maxima, which block the binding of [3H]-methyl quinuclidinyl benzilate to M1 (rat brain), M2 (rat
heart) and M3 (rat salivary gland) receptors [194]. It has been postulated that manzamines A and B are
formed biosynthetically by intramolecular Diels-Alder reaction of compounds related to the
cyclostellettamines which have a 2,3-dihydropyridinium ring (acting as the diene component) and
alkene groups in the linking carbon chains [195]. This proposal was validated in vitro by the
biomimetic synthesis of kermaphidin B, albeit the Diels-Alder reaction only gave a minuscule yield
(0.2-0.3%) [196]. The work described below may be regarded as a prelude to a thorough testing of the
biosynthetic Diels-Alder proposal.
The synthesis of 32-36-membered rings can at the very least be described as demanding! Base
treatment of the hydrochloride salt (174a, n = 7) resulted in nucleophilic addition to the pyridinium
ring to give a bis-Zincke salt which upon thermolysis yielded the 20-membered bis-pyridinium
macrocycle (177). However application of this methodology to the homologue (174b, n = 13) resulted
in exclusive formation of the product of intramolecular attack (176) and larger rings could only be
prepared by sequential alkylation [197].
N
Cl
N
N
NH3Cl
X
DNB
NH
HN
NHDNB
DNBHN
Et3N, BuOH, 20°C
BuOH,  
reflux
(175)
(177)
(174a) n = 7
N Cl
(174b) n = 13 
a Et3N, BuOH, 20°C; 
b BuOH, reflux;
DNB = 2,4-dinitrobenzene
(176)
(174)
The complete set of natural cyclostellettamines (173a-f) were prepared by stepwise pyridine
alkylation using a pyridinium N-oxide (178) and a hydroxyl group (179) as "protective groups". They
were converted to the pyridine and an alkyl bromide (181) in a single step by treatment with
phosphorus tribromide [198]. A comparable approach was used by Wanner and Koomen except that
the pyridine was protected by a p-methoxy-benzyl group [199].
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N
Cl
n
O
N
HO
m
N
n-3
N
m-3
PBr3, CHCl3
a K2CO3;
N
n-3
O
N
HO
m
N
n-3
N
Br
m
NaI, butan-2-one, ∆
(178)
 b NaI, butan-2-one, ∆∗
(62-66% yield)
(173 a-f)
(180)
(181)
(179)
H
In the final synthesis of cyclostellettamines, Wittig reactions were used to append the hydrocarbon
side chains, which resulted in an exercise in selective reduction and benzyl ether cleavage. The alkene
bonds were reduced by catalytic hydrogenation without reduction of the pyridine (cf. 183) or
pyridinium rings or cleavage of the benzylic ether (cf. 185). Cleavage of the benzyl ether (185) by
catalytic hydrogenation was precluded by the pyridinium ring, however treatment with
trifluoromethanesulfonic acid and trimethylsilyl iodide furnished the desired alcohol in 48% yield.
Sulfonate ester formation and cyclisation under high dilution conditions (0.5mM) furnished
cyclostellettamine C in good yield [200].
N
H
O
a BuLi, Ph3P(CH2)12OBn I (85% yield)
b H2, Pd-C, EtOH (90% yield) N
(CH2)13OBn
N
(CH2)13OBn
(CH2)12PPh3
Ph3P(CH2)12OH I, Tf2O, 
collidine, CH2Cl2 (85% yield)
N
N I, OTf
a NaH, THF, (182) (43% yield)
b H2, Pd-C, EtOH (36% yield)
10
OBn
10
N
N
10
10
a TfOH, CH2Cl2; b Me3SiI (48% yield)
b 0.5mM solution, Tf2O, collidine,  
CH2Cl2 (78% yield)
(182)
(183)
(185) (184)
(173c) Cyclostellettamine C
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7 Conclusions and Future Prospects
The identification and cloning of the muscarinic receptor subtypes was celebrated as the great
advance that would transform the study of muscarinics. However, thus far it has not proved possible to
prepare small ligands with sufficient selectivity to distinguish between them and achieve therapeutic
benefits. The paradigm of seeking partial agonists and exploiting effective receptor reserve has proved
to be more effective for producing therapeutically useful compounds. Albeit significant advances are
still required to effectively treat conditions such as Alzheimer's disease. Whereas a whole family of
peptide muscarinic (MTs) and other toxins have been isolated from the venom of the African green
mamba, Dendroapsis augusticeps  [201-202] which have extra-ordinary selectivity. The five to six fold
selectivity of pirenzepine (5) for m1 and tripitramine for m2 receptor subtypes is dwarfed by the 214
fold higher affinity of MT3 for m4 receptors over m1 and it has no significant binding to m2, m3 or m5
receptor subtypes [203]. Similarly M1-toxin is capable of blocking m1 receptors without affecting m2-
m5 [204] and 125I- labelled M1-toxin has been used to visualise the distribution of M1 sites in the brain
[205].
Millions of years of evolution constitutes the ultimate combinatorial laboratory. Nature continues
to provide novel muscarinics such as martinelline (used as an eye medication in South America) [206],
distantly related to the guanidino-derivatives (187) and novel polycyclic amines such as the TAN1251's
(188) [207]. No doubt these will provide leads for new classes of muscarinics.
N
H
O
O N
N N
N
N
HN
H
H H
NH
H
NH
H2N
(186) Martinelline
N
H
NH
H2N N NH2
O
N H
NH
4 2
3 1513
R H
(187a) R = Ac 
(187b) R = 9-Guanidinononanoyl
N
O
N
R
O (188a) R = H; TAN1251A 
(188B) R = OH; TAN1251B
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Postscript added in proof, Developments in Drugs for Alzheimer’s Disease (23rd January 2001):
The National Institute for Clinical Excellence (NICE) in the United Kingdom announced on the
19th January 2001 that three drugs: donepezil (Aricept), rivastigmine (Exelon) and galantamine
(Reminyl), should be prescribed for patients with mild and moderate forms of Alzheimer’s disease.
However, NICE has ruled that these drugs should not be made available by the National Health Service
to patients with more advanced symptoms because of a lack of proven clinical benefits
(http://news.bbc.co.uk/hi/english/health/newsid_1124000/1124794.stm). All three drugs are
cholinesterase inhibitors. Tacrine (13) which is also a cholinesterase inhibitor was the first drug
approved by the FDA (1993) for treating Alzheimer’s disease, but its use is decreasing in favour of
donepezil (approved 1996), which has a similar but more selective mode of action and hence has fewer
side effects. Moreover tacrine has a half life in the body of only 1.4 to 3.6 hours and hence has to be
given four times a day. In contrast, donepezil has a half life of 70 hours and a single daily dose is
sufficient.
Muscarinic agonists have fared less well. Sabcomeline (134b), milameline or RU 35926 (35b) and
physostigmine (12a) are all no longer in development. The oral formulation of xanomeline (34) has
also been withdrawn, but the skin patch continues in development. In most cases drugs these have been
withdrawn during phase III trials due to poor efficacy or side effects. It remains to be seen if sufficient
selective M1 agonist activity can be achieved without unacceptable side effects, whereas selectivity for
neuronal Ach esterase as opposed to peripheral non-neuronal butyrylcholinesterase appears to be more
easily attainable.
8 References
1. Broadley, K. J., Autonomic Pharmacology, Taylor & Francis: London, 1996.
2. Starke, K., Gothert, M. and Kilbinger, H. Physiol. Rev. 1989, 69, 864-989.
3. Newberry, N. R. and Priestley, T. Br. J. Pharmacol. 1987, 92, 817-826.
4. Hammer, R., Berrie, C. P., Birdsall, N. J. M., Burgen, A. S. V. and Hulme, E. C. Nature 1980,
283, 90-92.
5. International Union of Pharmacology XVIII classification of muscarinic acetylcholine receptors,
Caulfield, M. P., Birdsall, N. J. M. Pharmacol. Rev. 1998, 50, 279-290.
6. Reever, C. M., Ferrari-DiLeo, G. and Flynn, D. D. Life Sci. 1997, 60, 1105-1112.
7. Hulme, E. C., Birdsall, N. J. M. and Buckley, N. J. Annu. Rev. Pharmacol. Toxicol. 1990, 30,
633-673.
8. Caulfield, M. P. Pharmacol. Ther. 1993, 58, 319-379.
9. Eglen, R. M., Hegde, S. S. and Watson, N. Pharmacol. Rev. 1996, 48, 531-565.
10. Urquhart, R. A. and Broadley, K. J. Gen. Pharmacol. 1992, 23, 619-626.
11. Sneddon, P. and Graham, A. J. Auton. Pharmacol. 1992, 12, 445-456.
12. Eglen, R. M. and Whiting, R. L. J. Auton. Pharmacol. 1990, 10, 233-245.
13. Kromer, W. and Eltze, M. J. Auton. Pharmacol. 1991, 11, 337-342.
14. Goyal, R. K. N. Engl. J. Med. 1989, 321, 1022-1029.
Molecules 2001, 6 186
15. Alabaster, V. A. Life Sci. 1997, 60, 1053-1060.
16. Howell, R. E., Laemont, K. D., Kovalsky, M. P., Lowe, V. C., Waid, P. P., Kinnier, W. J. and
Noronha-Blob, L. J. Pharmacol. Exp. Ther. 1994, 270, 546-553.
17. Kaufman, P. L., Weidman, T. and Robinson, J. R. in Pharmacology of the Eye. Handbook of
Experimental Pharmacology (Sears, M. L., ed), pp. 149-191, Spriger-Verlag, Berlin, 1984.
18. Growdon, J. H. Life Sci. 1997, 60, 993-998.
19. Babic, T, Smith, R. J. and Petravic, D. Neurologia Croatica 1997, 46, 55-72.
20. Wen, G. Y. J. Food Drug. Anal. 1998, 6, 465- 476.
21. Huff, F. J., Mickel, S. F., Corkin, S. and Growdon, J. H. Drug Devel. Res. 1988, 12, 271-278.
22. Yankner, B. A., Duffy, K. L. and Kirschner, D. A. Science 1990, 250, 279-282.
23. Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H.
and Selkoe, D.J. J. Biol. Chem. 1993, 268, 22959-22962.
24. Muller, D. M., Mendla, K., Farber, S. A. and Nitsch, R. M. Life Sci. 1997, 60, 985-991.
25. Avery, E. E., Baker, L. D., Asthana, S. Drugs & Aging 1997, 11, 450-459.
26. Unni, L. K. CNS Drugs 1998, 10, 447-460.
27. Weinstock, M. Neurodegeneration 1995, 4,349-356.
28. Giacobini, E. Neurochem. Int. 1998, 32, 413-419.
29. Hunter, A. J., Murray, T. K., Jones, J. A., Cross, A. J. and Green, A. R. Br. J. Pharmacol. 1989,
98, 79-86.
30. Nordberg, A. and Svensson, A. L. Drug Safety 1998, 19, 465-480.
31. Doods, H. N., Quirion, R., Mihm, G., Engel, W., Rudolf, K., Entzeroth, M., Schiavi, G. B.,
Ladinsky, H., Bechtel, W. D., Ensinger, H. A., Mendla, K. D. and Eberlein, W. Life Sci. 1993, 52,
497-503.
32. Baker, R., Showell, G. A., Street, L. J., Saunders, J., Hoogsteen, K., Freedman, S. B., Hargreaves,
R. J. J. Chem. Soc., Chem. Commun. 1992, 817-819.
33. Street, L. J., Baker, R., Book, T., Reeve, A. J., Saunders, J., Willson, T., Marwood, R. S. Patel,
S., Freedman S. B. J. Med. Chem. 1992, 35, 295-305.
34. Baker, R., Street, L. J., Reeve, A. J., Saunders, J. J. Chem. Soc., Chem. Commun. 1991, 760-762.
35. Hargreaves, R. J., McKnight, A. T., Scholey, K., Newberry, N. R., Street, L. J., Hutson, P. H.,
Semark, J. E., Harley, E. A., Patel, S., Freedman, S. B. Br. J. Pharmacol. 1992, 107, 494-501.
36. Freedman, S. B., Dawson, G. R., Iversen, L. L., Baker, R. and Hargreaves, R. J. Life Sci. 1993,
52, 489-495
37. Ensinger, H. A., Bechtel, W. D., Birke, F. W., Mendla, K. D., Mierau, J., Speck, G., Troger, W.
Drug Devel. Res. 1997, 40, 144-157.
38. Adamus, W. S., Leonard, J. P. and Troger, W. Life Sci. 1995, 56, 883-890.
39. Schulte, B., Volz-Zang, C., Mutschler, E., Horne, C., Palm, D., Wellstein, A. and Pitschner, H.F.
Clin. Pharmacol. Ther. 1991, 50, 372-378.
40. Eglen, R. M. and Watson, N. Pharmacol. Toxicol. 1996, 78, 59-68.
41. Anerson, K.-E. Drugs 1988, 35, 477-494.
42. Langtry, H. D. and McTavish, D. Drugs 1990, 40, 748-761.
43. Nilvebrannt, L., Hallen, B. and Larsson, G. Life Sci. 1997, 60, 1129-1136.
44. Oyasu, H., Yamamoto, T., Sato, N., Ozaki, R., Mukai, T., Ozaki, T., Nishii, T., Sato, H.,
Fujisawa, T., Tozuka, Z., Koibuchi, Y., Honbo, T., Esumi, K., Ohtsuka, M. and Shimomura, K.
Arzneimittelforsch./Drug Res. 1994, 44, 1242-1249.
45. Barnes, P. J. Life Sci. 1993, 52, 521-527.
Molecules 2001, 6 187
46. Gross, N.J. in Asthma: Basic Mechanisms and Clinical Management 2nd Edn (Barnes, P. J.,
Rodger, I. W. and Thomson, N. C., eds.), pp. 555-566, Academic Press, London, 1992.
47. Maesen, F. P. V., Smeets, J. J., Costongs, M. A. L., Cornelissen, P. J. G. and Wald, F. D. M. Eur.
Resp. J. 1993, 6, 1031-1036.
48. Dail, W.G. in Nervous Control of the Urogenital System (Maggi, C.A., ed.), The Autonomic
Nervous System, vol. 3, pp. 69-101, Harwood: Switzerland, 1993.
49. Ruggieri, M. R., Colton, M. D., Wang, P., Wang, J., Smyth, R. J., Pontari, M. A. and Luthin, G.
R. J. Pharmacol. Exp. Ther. 1995, 274, 976-982.
50. Caine, M., Raz, S. and Zeigler, M. Br. J. Urol. 1975, 47, 193-202.
51. Lau, W. A. K., Pennefather, J. N. and Mitchelson, F. Proc. Aust. Soc. Clin. Exp. Pharmacol.
Toxicol. 1996, 110.
52. Holdsworth, D. K., Jones, R. A., Self, R. Phytochemistry 1998, 48, 581-582.
53. Wang, C. K., Lee, W. H., Peng, C. H. Agric. Biol. Chem. 1997, 45, 1185-1188.
54. Ref 1, p341.
55. Jeng, J. H., Hahn, L. J., Lin, B. R., Hsieh, C. C., Chan, C. P., Chang, M. C. J. Oral. Pathol. Med.
1999, 28, 64-71.
56. Sharan, R. N. Cancer J. 1996, 9, 13-19.
57. Raffaele, K. C., Berardi, A., Morris, P. P., Asthana, S., Haxby, J. V., Schapiro, M. B., Rapoport,
S. I., Soncrant, T. T. Prog. Neuro-Psychopharmacol. & Biol. Psychiatry 1991, 15, 643-648.
58. Raffaele, K. C., Berardi, A., Asthana, S., Morris, P., Haxby, J. V., Soncrant, T. T.
Psychopharmacology Bull. 1991, 27, 315-319.
59. Raffaele, K. C., Asthana, S., Berardi, A., Haxby, J. V., Morris, P. P., Schapiro, M. B., Soncrant,
T. T. Neuropsychopharmacology, 1996, 15, 163-170.
60. Soncrant, T. T., Raffaele, K. C., Asthana, S., Berardi, A., Morris, P. P., Haxby, J. V.
Psychopharmacology 1993, 112, 421-427.
61. Asthana, S., Raffaele, K. C., Greig, N. H., Berardi, A., Morris, P. P., Schapiro, M. B., Rapoport,
S. I., Blackman, M. R., Soncrant, T. T. Psychoneuroendocrinology 1995, 20, 623-636.
62. Asthana, S., Greig, N. H., Holloway, H. W., Raffaele, K. C., Berardi, A., Schapiro, M. B.,
Rapoport, S. I., Soncrant, T. T. Clin. Pharmacol. & Therap. 1996, 60, 276-282.
63. Law, M. Y. L., Pershing, L. K., Roberts, L. K. Int. J. Pharmaceutics 1992, 88, 251-260.
64. Kurihara-Bergstrom, T., Good, W. R., Feisullin, S., Signor, C. J. Control. Release 1991, 15, 271-
278.
65. Hussain, M. A., Mollica, J. A. J. Pharm. Sci. 1991, 80, 750751.
66. Patterson, T. A., Kosh, J. W. Gen. Pharmacol. 1993, 24, 641-647.
67. Moos, W. H., Bergmeier, S. G., Coughenour, L. L., Davis, R. E., Hershenson, F. M., Kester, J.
A., McKee, J. S., Marriott, J. G., Schwarz, R. D., Tecle, H., Thomas, A. J. J. Pharm. Sci. 1992,
81, 1015-1019.
68. Moser, U., Gubitz, C., Galvan, M., Immelsehr, A., Lambrecht, G., Mutschler, E., Drug Res.
1995, 45-1, 449-455.
69. Toja, E., Bonett, C., Butti, A., Hunt, P., Fortin, M., Barzaghi, F., Formento, M. L., Maggioni, A.,
Nencioni, A., Galliani, G. Eur. J. Med. Chem. 1991, 26, 853-868.
70. Toja, E., Bonett, C., Butti, A., Hunt, P., Fortin, M., Barzaghi, F., Formento, M. L., Maggioni, A.,
Nencioni, A., Galliani, G. Eur. J. Med. Chem. 1992, 27, 519-526.
71. Showell, G. A., Gibbons, T. L., Kneen, C. O., MacLeod, A. M., Merchant, K., Saunders, J.,
Freedman, S. B., Patel, S., Baker, R. J. Med. Chem. 1991, 34, 1086-1094.
Molecules 2001, 6 188
72. Moltzen, E. K., Pedersen, H., Bogeso, K. P., Meier, E., Frederiksen, K., Sanchez, C., Lembol,
H.L. J. Med. Chem. 1997, 37, 4085-4099.
73. Bymaster, F. P., Whitesitt, C. A., Shannon, H. E., DeLapp, N., Ward, J. S., Calligaro, D. O.,
Shipley, L. A., BuelkeSam, J. L., Bodick, N. C., Farde, L., Sheardown, M. J., Olesen, P. H.,
Hansen, K. T., Suzdak, P. D., Swedberg, M. D. B., Sauerberg, P., Mitch, C. H. Drug Dev. Res.
1997, 40, 158-170.
74. Christopoulos, A., Pierce, T. L., Sorman, J. L., El Fakahany, E. E. Mol. Pharmacol. 1998, 53,
1120-1130.
75. Christopoulos, A., El Fakahany, E. E. Eur. J. Pharmacol. 1997, 334, R3-R4.
76. DeLapp, N., Wu, S., Belagaje, R., Johnstone, E., Little, S., Shannon, H., Bymaster, F., Calligaro,
D., Mitch, C., Whitesitt, C., Ward, J., Sheardown, M., Fink-Jensen, A., Jeppesen, L., Thomsen,
C., Sauerberg, P. Biochem. Biophys. Res. Commun. 1998, 244, 156-160.
77. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H.
E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z., Paul, S. M.
Archiv. Neurol. 1997, 54, 465-473.
78. Bodick, N. C., Offen, W. W., Shannon, H. E., Satterwhite, J., Lucas, R., Van Lier, R., Paul, S. M.
Alzheimer Disease Assoc. Disorders 1997, 11, S16-S22.
79. Ward, J. S., Merritt, L., Stratford, R., Brown, T. J., Wijayaratne, R., Szewczyk, S. P., Calligaro,
D. O., Bymaster, F. P., Shannon, H. E., Mitch, C. H., Johnson, D.W., Wikel, J. H., Olesen, M. J.,
Sheardown, M. J., Swedberg, M. D. B., Sauerberg, P. Life Sci. 1997, 60, 6.
80. Ward, J. S., Merritt, L., Calligaro, D. O., Bymaster, F. P., Shannon, H. E., Sawyer, B. D., Mitch,
C. H., Deeter, J. B., Peters, S. C., Sheardown, M. J., Olesen, P.H., Swedberg, M. D. B.,
Sauerberg, P. J. Med. Chem. 1995, 38, 2469-3481.
81. Ward, J. S., Merritt, L., Klimkowski, V. J., Lamb, M. L., Mitch, C. H., Bymaster, F. P., Sawyer,
B., Shannon, H. E., Olesen, P. H., Honore, T., Sheardown, M. J., Sauerberg, P. J. Med. Chem.
1992, 35, 4011-4019.
82. Hass, K. and Wieland, A. Chem. Ber. 1960, 93, 1686-1692.
83. Spry, D. O. and Aaron, H. S. J. Org. Chem. 1969, 34, 3674-3676.
84. Barrett, S. D., Jaen, J. C., Caprathe, B. W., Thomas, A. J. and Tecle, H. Org. Prep. Proc. Int.
1997, 29, 330-335.
85. Aaron, H. S., Owens, O. O., Rosenstock, P. D., Leonard, S., Elkin, S. and Miller, J. I. J. Org.
Chem. 1965, 30, 1331-1333.
86. Nielson, A. T. and Platt, E. N. J. Heteocyclic Chem. 1969, 6, 891-900.
87. Nielson, A. T. J. Heterocyclic Chem. 1970, 7, 231-234.
88. Snow, R. J., Baker, R., Herbert, R. H., Hunt, I.. J., Merchant, K. J. and Saunders, J. J. Chem.
Soc., Perkin Trans. 1 1991, 409-420.
89. Review; Kazlauskas, R., Bornscheuer U. in Biotransformations, Volume 8a in the series
Biotechnology, Kelly, D. R. (ed.), Wiley-VCH, Weinheim, 37-192, 1998.
90. Guanti, G., Banfi, L., Brusco, S., Narisano, E. Tetrahedron: Asym. 1994, 5, 537-540.
91. Hanessian, S. Total Synthesis of Natural Products: The Chiron Approach, Pergamon: Oxford,
291pp, 1983.
92. Bols, M. Carbohydrate Building Blocks, Wiley: New York, 1996.
93. Fraser-Reid, B. O. Acc. Chem. Res. 1996, 29, 57-66
94. Nicolaou, K. C., Veale, C. A., Hwang, C. K., Hutchinson, J., Prasad, C. V. C., Ogilvie, W. W.
Angew. Chem. Int. Ed. Engl. 1991, 30, 299-303.
Molecules 2001, 6 189
95. Mori, K. Tetrahedron 1989, 45, 3233-3298.
96. Vazqueztato, M. P., Seijas, J. A., Fleet, G. W. J., Mathews, C. J., Hemmings, P. R., Brown, D.
Tetrahedron 1995, 51, 959-974.
97. Fleet, G. W. J., Mathews, C. J., Seijas, J. A., Tato, M. P. V., Brown, D. J. J. Chem. Soc., Perkin
Trans I 1989, 1065-1066.
98. Fleet, G. W. J., James, K., Lunn, R. J. Tetrahedron Lett. 1986, 27, 3053-3056.
99. Fleet, G. W. J., James, K., Lunn, R. J., C. J. Matthews Tetrahedron Lett. 1986, 27, 3057-3058.
100. Fleet, G. W. J., Mathews, C. J., Seijas, J. A., Tato, M. P. V., Brown, D. J. J. Chem. Soc., Perkin
Trans I 1989, 1067-1068.
101. Terao, Y., Kotake, H., Imai, N., Achiwa, K. Chem. Pharm. Bull. 1985, 33, 2762-2766.
102. Orlek, B. S., Wadsworth, H., Wyman, P., Hadley, M. S. Tetrahedron Lett. 1991, 32, 1241-1244.
103. Cotterell, I. F., Hands, D., Kennedy, D. J., Kerensa, J. P., Wright, S. H. B., Hoogsteen, K. J.
Chem. Soc., Perkin Trans I 1990, 1091-1097.
104. Orlek, B. S., Wadsworth, H., Wyman, P., Hadley, M. S. Tetrahedron Lett. 1991, 32, 1245-1246.
105. Jenkins, S. M., Wadsworth, H. J., Bromidge, S., Orlek, B. S., Wyman, P. A., Riley, G. J.,
Hawkins, J. J. Med. Chem. 1992, 35, 2392-2406.
106. Diana, G. D., Volkots, D. L., Nitz, T. J., Bailey, T. R., Long, M. A., Vescio, N., Aldous, S.,
Pevear, D. C., Dutko, F. J. J. Med. Chem. 1994, 37, 2421-2436.
107. Andersen, K. E., Lundt, B. F., Jorgensen, A. S., Braestrup, C. Eur. J. Med. Chem. 1996, 31, 417-
425.
108. Street, L. J., Baker, R., Book, T., Kneen, C. O., Macleod, A. M., Merchant, K. J., Showell, G. A.,
Saunders, J., Herbert, R. H., Freedman, S. B., Harley, E. A. J. Med. Chem. 1990, 33, 2690-2697.
109. Macor, J. E., Ordway, T., Smith, R. L., Verhoest, P. R., Mack, R. A. J. Org. Chem. 1996, 61,
3228-3229.
110. Saunders, J., MacLeod, A. M., Merchant, K., Showell, G. A., Snow, R. J., Street, L. J., Baker, R.
J. Chem. Soc., Chem. Commun. 1988, 1618-1619.
111. Sternbach, L. H., Kaiser, S. J. Am. Chem. Soc. 1952, 74, 2215-18 & 2219-2221.
112. Daeniker, H. U., Grob, C. A. Org. Syn. Coll. V 1973, 989-993.
113. Grob, C.A., Renk, E. Helv. Chim. Acta. 1954, 37, 1672-1680 & 1681-1688 & 1689-1698.
114. Snow, R. J., Baker, R., Herbert, R. H., Hunt, I. J., Merchant, K. J., Saunders, J. J. Chem. Soc.,
Perkin Trans. 1 1991, 409-420.
115. Saunders, J., MacLeod, A. M., Merchant, K., Showell, G. A., Snow, R. J., Street, L. J., Baker, R.
J. Chem. Soc., Chem. Commun. 1988, 1618-1619.
116. Street, L. J., Baker, R., Book, T., Kneen, C. O., Macleod, A. M., Merchant, K. J., Showell, G. A.,
Saunders, J., Herbert, R. H., Freedman, S. B., Harley, E. A. J. Med. Chem. 1990, 33, 2690-2697.
117. MacLeod, A. M., Herbert, R., Hoogsteen, K. J. Chem. Soc., Chem. Commun. 1990, 100-102.
118. Jenkins, S. M., Wadsworth, H. J., Bromidge, S., Orlek, B. S., Wyman, P. A., Riley, G. J.,
Hawkins, J. J. Med. Chem. 1992, 35, 2392-2406.
119. Boelsterli, J., Eggnauer, U., Pombo-Villar, E., Weber, H.-P., Walkinshaw, M. Helv. Chim. Acta.
1992, 75, 507-512.
120. Showell, G. A., Baker, R., Davis, J., Hargreaves, R., Freedman, S. B., Hoogsteen, K., Patel, S.,
Snow, R. J. J. Med. Chem. 1992, 35, 911-916.
121. Freedman, S. B., Harley, E. A., Marwood, R. S., Patel, S. Eur. J. Pharmacol. 1990, 187, 193-199.
Molecules 2001, 6 190
122. Freedman, S. B., Harley, E. A., Patel, S., Newberry, N., Gilbert, A. T., McKnight, A., Tang, J. K.,
Macquire, J. J., Mudunkotuwa, N. T., Baker, R., Street, L. J., MacLeod, A. M., Saunders, J.,
Iversen, L. L. Br. J. Pharamacol. 1990, 101, 575-580.
123. Baker, R., Showell, G. A., Street, L. J., Saunders, J., Hoogsteen, K., Freedman, S. B., Hargreaves,
R. J. J. Chem. Soc., Chem. Commun. 1992, 817-819.
124. Freedman, S. B., Patel, S., Harley, E. A., Iversen, L. L., Baker, R., Showell, G. A., Saunders, J.,
McKnight, A., Newberry, N., Scholey, K., Hargreaves, R. Eur. J. Pharamacol. 1992, 215, 135-
136.
125. Baker, R., Street, L. J., Reeves, A. J., Saunders J. Chem. Soc., Chem. Commun. 1991, 760-762.
126. Street, L. J., Baker, R., Book, T., Reeve, A. J., Saunders, J., Willson, T., Marwood, R. S., Patel,
S., Freedman, S. B. J. Med. Chem. 1992, 35, 295-305.
127. Ashwood, M. S., Gibson, A. W., Houghton, P. G., Humphrey, G. R., Roberts, D. G., Wright, S.
H. B. J. Chem. Soc., Perk. Trans. I. 1995, 641-644.
128. Hargreaves, R. J., McKnight, A. T., Scholey, K., Newberry, N. R., Street, L. J., Hutson, P. H.,
Semark, J. E., Harley, E. A., Patel, S., Freedman, S. B. Br. J. Pharmacol. 1992, 107, 494-501.
129. Freedman, S. B., Dawson, G. R., Iverson, L. L., Baker, R., Hargreaves, R. J. Life Sci. 1993, 52,
489-495.
130. Loudon, J. M., Bromidge, S. M., Brown, F., Clark, M. S. G., Hatcher, J. P., Hawkins, J., Riley,
G. J., Noy, G., Orlek, B. S. J. Pharmacol. Exper. Therap. 1997, 283, 1059-1068.
131. Bromidge, S. M., Cassidy, F., Clark, M. S. G., Eggleston, D. S., Oriek, B. S. J. Chem. Soc.,
Chem. Commun. 1994, 2189-2190
132. Bromidge, S. M., Brown, F., Cassidy, F., Clark, M. S. G., Dabbs, S., Hadley, M. S., Hawkins, J.,
Loudon, J. M., Naylor, C. B., Orlek, B. S., Riley, G. J. J. Med. Chem. 1997, 40, 4265-4280.
133. Harries, M. H., Samson, N. A., Cilia, J., Hunter, A. J. Br. J. Pharmacol. 1998, 124, 409-415.
134. Hatcher, J. P., Loudon, J. M., Hagan, J. J., Clark, M. S. G. Psychopharmacology 1998, 138, 275-
282.
135. Grochowski, E., Jurczak, J. Synthesis 1976, 682-684; for recent examples see Maier, L., Sporri,
H. Phosph. Sulfur & Related Element 1992, 70, 39-48 & 49-57.
136. Tecle, H., Jaen, J. C., Augelli-Szafran, C., Barrett, S. D., Caprathe, B. W., Lauffer, D. J.,
Mirzadegan, T., Moos, W. H., Moreland, D. W., Pavia, M. R., Schwarz, R. D., Thomas, A. J.,
Davis, R. E. Bioorg. Med. Chem. Lett. 1995, 5, 631-636.
137. Tecle, H., Lauffer, D. J., Davis, R. E., Mirzadegan, T., Moreland, D. W., Schwarz, R. D.,
Thomas, A. J., Raby, C., Eubanks, D., Brann, M. R., Jaen, J. C. Bioorg. Med. Chem. Lett. 1995,
5, 637-642.
138. Jaen, J. C., Barrett, S., Brann, M., Callahan, M. J., Davis, R., Doyle, P., Eubanks, D., Lauffer, D.,
Lauffer, L, Lipiniski, W., Moreland, D. W., Nelson, C. B., Raby, C., Schwarz, R., Spencer, C.,
Tecle, H. Life Sci. 1995, 56, 845-852.
139. Tecle, H., Barrett, S.D., Lauffer, D. J., Augelli-Szafran, C., Brann, M. R., Callahan, M. J.,
Caprathe, B. W., Davis, R. E., Doyle, P. D., Eubanks, D., Lipiniski, W., Mirzadegan, T., Moos,
W. H., Moreland, D. W., Nelson, C. B., Pavia, M. R., Raby, C., Schwarz, R. D., Spencer, C. J.,
Thomas, A. J., Jaen, J. C. J. Med. Chem. 1998, 41, 2524-2536.
140. Hills, C. J., Winter, S. A., Balfour, J. A. Drugs 1998, 55, 813-820.
141. Gillberg, P.G., Sundquist, S., Nilvebrant, L. Eur. J. Pharmacol. 1998, 349, 285-292.
142. Postlind, H., Danielson, A., Lindgren, A., Andersson, S. H. G. Drug Metab. Disp. 1998, 26, 289-
293.
Molecules 2001, 6 191
143. Andersson, S. H. G., Lindgren, A., Postlind, H. Drug Metab. Disp. 1998, 26, 528-535.
144. Nilvebrant, L., Gillberg, P. G., Sparf, B. Pharmacol. & Toxicol. 1997, 81, 169-172.
145. Nilvebrant, L., Hallen, B., Larsson, G. Life Sci. 1997, 60, 1129-1136.
146. Brynne, N., Dalen, P., Alvan, G., Bertilsson, L., Gabrielsson, J. Clin. Pharmacol. Therap. 1998
63, 529-539.
147. Swart, R., Koivisto, P., Markides, K. E. J. Chromatog. A. 1998, 828, 209-218.
148. Palmer, L., Andersson, L., Andersson, T., Stenberg, U. J. Pharm. Biomed. Anal. 1997, 16, 155-
165.
149. For a review of asymmetric conjugate additions see Rossiter, B.E., Swingle, N. M. Chem. Rev.
1992, 92, 771-806.
150 For a review of the use of chiral oxazolidinones in asymmetric synthesis see Ager, D. J., Prakash,
I., Schaad, D. R. Aldrichimica Acta 1997, 30, 3-12.
151. Andersson, P. G., Schink, H. E. and Osterlund, K. J. Org. Chem. 1998, 63, 8067-8070.
152. Leu, B. S., Li, G. G., Lung, F. D., Hruby, V. J. J. Org. Chem. 1995, 60, 5509-5514.
153. Barbier, P., Renzetti, A. R., Turbanti, L., Di Bugno, C., Fornai, F., Vaglini, F., Maggio, R.,
Corsini, G. U. Eur J. Pharm. 1995, 290, 125-132.
154. Review; Kazlauskas, R., Bornscheuer U. in Biotransformations, Volume 8a in the series
Biotechnology, Kelly, D. R. (ed.), Wiley-VCH: Weinheim, 37-192 1998.
155. Di Bussolo, V., Catelani, G. Mastrorilli, E., Di Bugno, C., Giorgi, R. Tetrahedron: Asym. 1996,
7, 3585-3592.
156. Di Bugno, C., Colombani, S.M., Dapporto, P., Garzelli, G., Paoli, P., Subissi, A., Turbanti
Chirality 1997, 9, 713-721.
157. Frey, K. A., Minoshima, S., Kuhl, D. E. Quart. J. Nucl. Med. 1998, 42, 166-178.
158. Morgan, A. E., Brodie, J. D., Dewey, S. L. Quart. J. Nucl. Med. 1998, 42, 151-157.
159. Maziere, M. Pharmacol. Therap. 1995, 66, 83-101.
160. Mullan, B. P., O'Connor, M. K., Hung, J. C. Neurosurgery Clinics of North Am. 1996, 7, 617-
652.
161. Devous, M. D. J. Neuroimaging 1995, 5, S2-S13.
162. Waldemar, G. Cerebrovascular Brain Metab. Rev. 1995, 7, 89-130
163. Knapp, F. F., McPherson, D. W., Luo, H., Zeeburg, B. Anticancer Res. 1997, 17, 1559-1572.
164. Kiesewetter, D. O., Carson, R. E., Jagoda, E. M., Herscovitch, P., Eckelman, W. C. Life Sci.
1998, 64, 511-518.
165. Lee., K. S., He, X. S., Jones, D. W., Coppola, R., Gorey, J. G., Knable, M. B., de Costa, B. R.,
Rice, K. C., Weinberger, D. R. J. Nucl. Med. 1996, 37, 2021-2024.
166. Seebach, D., Naef, R., Calderari, G. Tetrahedron 1984, 40, 1313-1324.
167. McPherson, D. W., Knapp, Jr. F. F. J. Org. Chem. 1996, 61, 8335-8336.
168. McPherson, D. W., Lambert, C. R., Jahn, K., Sood, V., McRee, R. C., Zeeberg, B., Reba, R. C.,
Knapp Jr., F. F. J. Med. Chem. 1995, 38, 3908-3917.
169. Cohen, V. I., Zeeberg, B. R., Boulay, S. F., Sood, V. K., Rayeq, M. R., Danesh, R. A.,
McPherson, D. W., Reba, R. C. J. Mol. Neuroscience 1998, 11, 1-9.
170. Ichihara, A., Oikawa, H., Curr. Org. Chem. 1998, 2, 365-394.
171. Katayama, K., Kobayashi, T., Oikawa, Honma, M. H., Ichihara, A. Biochim. Biophys. Acta 1998,
1384, 387-395.
172. Oikawa, H., Kobayashi, T., Katayama, K., Suzuki, Y., Ichihara, A. J. Org. Chem. 1998, 63, 8748-
8756.
Molecules 2001, 6 192
173. Oikawa, H., Yagi, K., Watanabe, K., Honma, M., Ichihara, A. J. Chem. Soc., Chem. Commun.
1997, 97-98.
174. Ichihara A. and Oikawa H. Biosci. Biotech. Bioch. 1997, 61, 12-18.
175. Jakubik, J., Bacakova, L., El Fakahany, E. E., Tucek, S. Mol. Pharmacol. 1997, 52, 172-179.
176. Dolezal, V., Tucek, S. Br. J. Pharmacol. 1998, 124, 1213-1218.
177. Lazareno, S., Gharagozloo, P., Kuonen, D., Popham, A., Birdsall, N. J. M. Mol. Pharmacol.
1998, 53, 573-589; correction 1999, 55, 194.
178. Gharagozloo, P., Miyauchi, M., Birdsall, B., Birdsall, N. J. M. J. Org. Chem. 1998, 63, 1974-
1980.
179. Lazareno, S., Birdsall, B., Fukazawa, T., Gharagozloo, P., Hashimoto, T., Kuwano, H., Popham,
A., Sugimoto, M., Birdsall, N. J. M Life Sci. 1999, 64, 519-526.
180. Dorje, F., Wess, J., Lambrecht, G., Tacke, R., Mutschler, E., Brann, M. R. J. Pharmacol. &
Exper. Therap. 1991, 256, 727-733.
181. Kilbinger, H., Von Bardeleben, R. S., Siefken, H., Wolf, D. Life Sci. 1995, 56, 981-987.
182. Matsui, H., Lazareno, S., Birdsall, N. J. M. Mol. Pharmacol. 1995, 47, 88-98.
183. Kozikowski, A. P., Fauq, A. H., Miller, J. H., McKinney, M. Bioorg. Med. Chem. Lett. 1992, 2,
797-802.
184. Malaska, M. J., Fauq, A. H., Kozikowski, A. P., Aagaard, P. J., McKinney, M. Bioorg. Med.
Chem. Lett. 1995, 5, 61-66.
185. Malaska, M. J., Fauq, A. H., Kozikowski, A. P., Aagaard, P. J., McKinney, M. Bioorg. Med.
Chem. Lett. 1993, 3, 1247-1252.
186. Baldwin, J. E., Chesworth, R., Parker, J. S., Russell, A. T. Tetrahedron Lett. 1995, 36, 9551-
9554.
187. Debaecke, G. and Declercq, P. J. Tetrahedron Lett. 1995, 36, 7515-7518.
188. Hofman, S., DeBaecke, G., Kenda, B., DeClerg, P. J. Synthesis 1998, 479-489.
189. Hart, D. J., Wu, W. L. and Kozikowski, A. P. J. Am. Chem. Soc. 1995, 117, 9369-9370.
190. Hart, D. J., Li, J., Wu, W. L. and Kozikowski, A. P. J. Org. Chem. 1997, 62, 5023-5033.
191. Chackalamannil, S., Davies, R. J., Asberom, T., Doller, D., Leone, D. J. Am. Chem. Soc. 1996,
118, 9812-9813.
192. Andersen, R. J., Van Soest, R. W. M and Kong, F. in Alkaloids; Chemical and Biological
Perspectives (Pelletier, S. W. ed.), pp301-355, Pergamon Press/Elsevier Science: Oxford, UK,
1996.
193. Tsuda, M., Kobayashi, J. Heterocycles 1997, 46, 765-794.
194. Fusetani, N., Asai, N., Matsunaga, S., Honda, K. and Yasumuro, K. Tetrahedron Lett. 1994, 35,
3967-3970.
195. Baldwin, J. E., Whitehead, R. C. Tetrahedron Lett. 1992, 33, 2059-2062.
196. Baldwin, J. E., Claridge, T. D. W., Culshaw, A. J., Heupel, F. A., Lee, V., Spring, D. R.,
Whitehead, R. C., Broughtflower, R. J., Mutton, I. M., Upton, R. J. Angew. Chem. Int. Ed. Engl.
1998, 37, 2661-2663.
197. Kaiser, A., Billot, X., Gateau-Olesker, A., Marazano, C. and Das, B. C. J. Am. Chem. Soc. 1998,
120, 8026-8034.
198. Baldwin, J. E., Spring, D. R., Atkinson, C. E. and Lee, V. Tetrahedron 1998, 54, 13655-13680.
199. Wanner, M. J. and Koomen, G. J. Eur. J. Org. Chem. 1998, 889-895.
200. Anan, H., Seki, N., Noshiro, O., Honda, K., Yasumuro, K., Ozasa, T. and Fusetani, N.
Tetrahedron 1996, 52, 10849-10860.
Molecules 2001, 6 193
201. Adem, A., Karlsson, E. Life Sci. 1997, 60, 1069-1076.
202. Liang, J. S., Carsi-Gabrenas, J., Krajewski, J. L., McCaffrey, J. M., Purkerson, S. L., Santiago,
M.P., Strauss, W. L., Valentine, H. H., Potter, L. T. Toxicon, 1996, 34, 1257-1267.
203. Jerusalinsky, D., Kornisiuk, E., Alfaro, P., Quillfeldt, J., Alonso, M., Verde, E. R., Cervenansky,
C., Harvey, A. Neuroreport, 1998, 9, 1407-1411.
204. Potter, L. T., Hanchett-Valentine, H., Liang, J.-S., Max, S. I., Purkerson, S. L., Silberberg, H. A.,
Strauss, W. L. Life Sci. 1993, 52, 433-440.
205. Adem, A., Jolkkonen, M., Bogdanovic, N., Islam, A., Karlsson, E. Brain. Res. Bull. 1997, 44,
597-601.
206. Witherup, K. M., Ransom, R. W., Graham, A. C., Bernard, A. M., Salvatore, M. J., Lumma,
W.C., Anderson, P. S., Pitzenberger, S. M., Varga, S. L. J. Am. Chem. Soc. 1995, 117, 6682-
6685.
207. Nagumo, S., Nishida, A., Yamazaki, C., Murashige, K., Kawahara, N. Tetrahedron Lett. 1998,
39, 4493-4496.
Sample Availability: Not applicable.
© 2001 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial purposes
